{"messages":[{"status":"ok","cursor":"2070","count":30,"total":9467}], "collection":[{"rel_doi":"10.1101\/2020.08.05.20168146","rel_title":"Clinical Mortality Review in a Large COVID-19 Cohort","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.05.20168146","rel_abs":"Background: Northwell Health (Northwell), an integrated health system in New York, treated more than 15000 inpatients with coronavirus disease (COVID-19) at the US epicenter of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. We describe the demographic characteristics of COVID-19 mortalities, observation of frequent rapid response teams (RRT)\/cardiac arrest (CA) calls for non-intensive care unit (ICU) patients, and factors that contributed to RRT\/CA calls. Methods: A team of registered nurses reviewed medical records of inpatients who tested positive for SARS-CoV-2 via polymerase chain reaction (PCR) before or on admission and died between March 13 (first Northwell inpatient expiration) and April 30, 2020 at 15 Northwell hospitals. Findings for these patients were abstracted into a database and statistically analyzed. Findings: Of 2634 COVID-19 mortalities, 56.1% had oxygen saturation levels greater than or equal to 90% on presentation and required no respiratory support. At least one RRT\/CA was called on 42.2% of patients at a non-ICU level of care. Before the RRT\/CA call, the most recent oxygen saturation levels for 76.6% of non-ICU patients were at least 90%. At the time RRT\/CA was called, 43.1% had an oxygen saturation less than 80%. Interpretation: This study represents one of the largest cohorts of reviewed mortalities that also captures data in non-structured fields. Approximately 50% of deaths occurred at a non-ICU level of care, despite admission to the appropriate care setting with normal staffing. The data imply a sudden, unexpected deterioration in respiratory status requiring RRT\/CA in a large number of non-ICU patients. Patients admitted to a non-ICU level of care suffer rapid clinical deterioration, often with a sudden decrease in oxygen saturation. These patients could benefit from additional monitoring (eg, continuous central oxygenation saturation), although this approach warrants further study.","rel_num_authors":7,"rel_authors":[{"author_name":"Mark P Jarrett","author_inst":"Donald and Barbara Zucker School at Hofstra\/Northwell"},{"author_name":"Susanne F Schultz","author_inst":"Northwell Health"},{"author_name":"Julie S Lyall","author_inst":"Northwell Health"},{"author_name":"Jason J Wang","author_inst":"Donald and Barbara Zucker School at Hofstra\/Northwell"},{"author_name":"Lori Stier","author_inst":"Northwell Health"},{"author_name":"Marcella De Geronimo","author_inst":"NorthwellHealth"},{"author_name":"Karen L Nelson","author_inst":"Donald and Barbara Zucker School at Hofstra\/Northwell"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.05.20168716","rel_title":"Rapid systematic review of the sensitivity of SARS-CoV-2 molecular testing on saliva compared to nasopharyngeal swabs","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.05.20168716","rel_abs":"ABSTRACT Background: Nasopharyngeal sampling has been the standard collection method for COVID-19 testing. Due to its invasive nature and risk of contamination for health care workers who collect the sample, non-invasive and safe sampling methods like saliva, can be used alternatively. Methods: A rapid systematic search was performed in PubMed and medRxiv, with the last retrieval on June 6th, 2020. Studies were included if they compared saliva with nasopharyngeal sampling for the detection of SARS-CoV-2 RNA using the same RT-qPCR applied on both types of samples. The primary outcome of interest was the relative sensitivity of SARS-CoV-2 testing on saliva versus nasopharyngeal samples (used as the comparator test). A secondary outcome was the proportion of nasopharyngeal-positive patients that tested also positive on a saliva sample. Results: Eight studies were included comprising 1070 saliva-nasopharyngeal sample pairs allowing assessment of the first outcome. The relative sensitivity of SARS-CoV-2 testing on saliva versus nasopharyngeal samples was 0.97 (95% CI=0.92-1.02). The second outcome incorporated patient data (n=257) from four other studies (n=97 patients) pooled with four studies from the first outcome (n=160 patients). This resulted in a pooled proportion of nasopharyngeal positive cases that was also positive on saliva of 86% (95% CI=77-93%). Discussion: Saliva could potentially be considered as an alternative sampling method when compared to nasopharyngeal swabs. However, studies included in this review often were small and involved inclusion of subjects with insufficient information on clinical covariates. Most studies included patients who were symptomatic (78%, 911\/1167). Therefore, additional and larger studies should be performed to verify the relative performance of saliva in the context of screening of asymptomatic populations and contact-tracing.","rel_num_authors":6,"rel_authors":[{"author_name":"Eliana Peeters","author_inst":"Sciensano"},{"author_name":"Sharon Kaur Dhillon Ajit Singh","author_inst":"Sciensano"},{"author_name":"Jo Vandesompele","author_inst":"Biogazelle"},{"author_name":"Pieter Mestdagh","author_inst":"Biogazelle"},{"author_name":"Veronik Hutse","author_inst":"Sciensano"},{"author_name":"Marc Arbyn","author_inst":"Sciensano"},{"author_name":"Karen L Nelson","author_inst":"Donald and Barbara Zucker School at Hofstra\/Northwell"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.05.20168757","rel_title":"Epidemiology of Reopening in the COVID-19 Pandemic in the United States, Europe and Asia","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.05.20168757","rel_abs":"Since the discovery of the novel coronavirus (SARS-CoV-2), COVID-19 has become a global healthcare and economic crisis. The United States (US) and Europe exhibited wide impacts from the virus with more than six million cases by the time of our analysis. To inhibit spread, stay-at-home orders and other non-pharmaceutical interventions (NPIs) were instituted. Beginning late April 2020, some US states, European, and Asian countries lifted restrictions and started the reopening phases. In this study, the changes of confirmed cases, hospitalizations, and deaths were analyzed after reopening for 11 countries and 40 US states using an interrupted time series analysis. Additionally, the distribution of these categories was further analyzed by age due to the known increased risk in elderly patients. Reopening had varied effects on COVID-19 cases depending on the region. Recent increases in cases did not fully translate into increased deaths. Eight countries had increased cases after reopening while only two countries showed the same trend in deaths. In the US, 30 states had observed increases in cases while only seven observed increased deaths. In addition, we found that states with later reopening dates were more likely to have significant decreases in cases, hospitalizations, and deaths. Furthermore, age distributions through time were analyzed in relation to COVID-19 in the US. Younger age groups typically had an increased share of cases after reopening.","rel_num_authors":5,"rel_authors":[{"author_name":"Weiqi Zhang","author_inst":"Merck Holding (China), Shanghai, China, a business of Merck KGaA, Darmstadt, Germany"},{"author_name":"Alina Oltean","author_inst":"MilliporeSigma, St. Louis, Missouri, a business of Merck KGaA, Darmstadt, Germany"},{"author_name":"Scott Nichols","author_inst":"MilliporeSigma, St. Louis, Missouri, a business of Merck KGaA, Darmstadt, Germany"},{"author_name":"Fuad Odeh","author_inst":"MilliporeSigma, St. Louis, Missouri, a business of Merck KGaA, Darmstadt, Germany"},{"author_name":"Fei Zhong","author_inst":"MilliporeSigma, St. Louis, Missouri, a business of Merck KGaA, Darmstadt, Germany"},{"author_name":"Marc Arbyn","author_inst":"Sciensano"},{"author_name":"Karen L Nelson","author_inst":"Donald and Barbara Zucker School at Hofstra\/Northwell"}],"version":"1","license":"cc_by","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.04.20167874","rel_title":"Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.04.20167874","rel_abs":"The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is due to the high rates of transmission by individuals who are asymptomatic at the time of transmission. Frequent, widespread testing of the asymptomatic population for SARS-CoV-2 is essential to suppress viral transmission and is a key element in safely reopening society. Despite increases in testing capacity, multiple challenges remain in deploying traditional reverse transcription and quantitative PCR (RT-qPCR) tests at the scale required for population screening of asymptomatic individuals. We have developed SwabSeq, a high-throughput testing platform for SARS-CoV-2 that uses next-generation sequencing as a readout. SwabSeq employs sample-specific molecular barcodes to enable thousands of samples to be combined and simultaneously analyzed for the presence or absence of SARS-CoV-2 in a single run. Importantly, SwabSeq incorporates an in vitro RNA standard that mimics the viral amplicon, but can be distinguished by sequencing. This standard allows for end-point rather than quantitative PCR, improves quantitation, reduces requirements for automation and sample-to-sample normalization, enables purification-free detection, and gives better ability to call true negatives. We show that SwabSeq can test nasal and oral specimens for SARS-CoV-2 with or without RNA extraction while maintaining analytical sensitivity better than or comparable to that of fluorescence-based RT-qPCR tests. SwabSeq is simple, sensitive, flexible, rapidly scalable, inexpensive enough to test widely and frequently, and can provide a turn around time of 12 to 24 hours.","rel_num_authors":31,"rel_authors":[{"author_name":"Joshua S. Bloom","author_inst":"University of California, Los Angeles"},{"author_name":"Eric M. Jones","author_inst":"Octant Inc."},{"author_name":"Molly Gasperini","author_inst":"Octant Inc."},{"author_name":"Nathan B. Lubock","author_inst":"Octant Inc."},{"author_name":"Laila Sathe","author_inst":"University of California, Los Angeles"},{"author_name":"Chetan Munugala","author_inst":"University of California, Los Angeles"},{"author_name":"A. Sina Booeshaghi","author_inst":"California Institute of Technology"},{"author_name":"Oliver F. Brandenberg","author_inst":"University of California, Los Angeles"},{"author_name":"Longhua Guo","author_inst":"University of California, Los Angeles"},{"author_name":"James Boocock","author_inst":"University of California, Los Angeles"},{"author_name":"Scott W. Simpkins","author_inst":"Octant Inc."},{"author_name":"Isabella Lin","author_inst":"University of California, Los Angeles"},{"author_name":"Nathan LaPierre","author_inst":"University of California, Los Angeles"},{"author_name":"Duke Hong","author_inst":"University of California, Los Angeles"},{"author_name":"Yi Zhang","author_inst":"University of California, Los Angeles"},{"author_name":"Gabriel Oland","author_inst":"University of California Los Angeles"},{"author_name":"Bianca Judy Choe","author_inst":"University of California, Los Angeles"},{"author_name":"Sukantha Chandrasekaran","author_inst":"University of California, Los Angeles"},{"author_name":"Evann E. Hilt","author_inst":"University of California, Los Angeles"},{"author_name":"Manish J. Butte","author_inst":"University of California, Los Angeles"},{"author_name":"Robert Damoiseaux","author_inst":"University of California, Los Angeles"},{"author_name":"Aaron R. Cooper","author_inst":"Octant Inc."},{"author_name":"Yi Yin","author_inst":"University of California, Los Angeles"},{"author_name":"Lior Pachter","author_inst":"California Institute of Technology"},{"author_name":"Omai B. Garner","author_inst":"University of California, Los Angeles"},{"author_name":"Jonathan Flint","author_inst":"University of California, Los Angeles"},{"author_name":"Eleazar Eskin","author_inst":"University of California, Los Angeles"},{"author_name":"Chongyuan Luo","author_inst":"University of California, Los Angeles"},{"author_name":"Sriram Kosuri","author_inst":"Octant Inc."},{"author_name":"Leonid Kruglyak","author_inst":"University of California, Los Angeles"},{"author_name":"Valerie A. Arboleda","author_inst":"University of California, Los Angeles"}],"version":"1","license":"cc_by","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.04.20168450","rel_title":"Social Behaviors Associated with a Positive COVID-19 Test Result","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.04.20168450","rel_abs":"Objective: To compare behaviors of individuals who tested positive for COVID-19 relative to non-infected individuals. Methods: We sent COVID positive cases and age\/gender matched controls a survey regarding their social behaviors via MyChart (online patient portal). We called cases if they did not complete the electronic survey within two days. Data was collected from May-June 2020. Survey responses for cases without a close contact and controls were compared using Pearson chi-square or Fishers Exact tests as appropriate. Results: A total of 339 participants completed the survey (113 cases, 226 controls); 45 (40%) cases had known contact with COVID-19. Cases were more likely to have recently traveled (4% vs. 0%, p=0.01) or to work outside the home (40% vs. 25%, p=0.02). There was no difference in the rates of attending private or public gatherings, mask\/glove use, hand-washing, cleaning surfaces and cleaning mail\/groceries between cases and controls. Conclusions: Sixty percent of cases had no known contact with COVID-19, indicating ongoing community transmission and underlining the importance of contact tracing. The greater percentage of cases who work outside the home provides further evidence for social distancing.","rel_num_authors":8,"rel_authors":[{"author_name":"Sidra Speaker","author_inst":"Cleveland Clinic Lerner College of Medicine of Case Western Reserve University"},{"author_name":"Christine Marie Doherty","author_inst":"Cleveland Clinic Lerner College of Medicine of Case Western Reserve University"},{"author_name":"Elizabeth R Pfoh","author_inst":"Cleveland Clinic"},{"author_name":"Aaron Dunn","author_inst":"Cleveland Clinic Lerner College of Medicine of Case Western Reserve University"},{"author_name":"Bryan Hair","author_inst":"Cleveland Clinic Lerner College of Medicine of Case Western Reserve University"},{"author_name":"Victoria Shaker","author_inst":"Cleveland Clinic"},{"author_name":"Lynn Daboul","author_inst":"Cleveland Clinic Lerner College of Medicine of Case Western Reserve University"},{"author_name":"Michael B Rothberg","author_inst":"Cleveland Clinic"},{"author_name":"Longhua Guo","author_inst":"University of California, Los Angeles"},{"author_name":"James Boocock","author_inst":"University of California, Los Angeles"},{"author_name":"Scott W. Simpkins","author_inst":"Octant Inc."},{"author_name":"Isabella Lin","author_inst":"University of California, Los Angeles"},{"author_name":"Nathan LaPierre","author_inst":"University of California, Los Angeles"},{"author_name":"Duke Hong","author_inst":"University of California, Los Angeles"},{"author_name":"Yi Zhang","author_inst":"University of California, Los Angeles"},{"author_name":"Gabriel Oland","author_inst":"University of California Los Angeles"},{"author_name":"Bianca Judy Choe","author_inst":"University of California, Los Angeles"},{"author_name":"Sukantha Chandrasekaran","author_inst":"University of California, Los Angeles"},{"author_name":"Evann E. Hilt","author_inst":"University of California, Los Angeles"},{"author_name":"Manish J. Butte","author_inst":"University of California, Los Angeles"},{"author_name":"Robert Damoiseaux","author_inst":"University of California, Los Angeles"},{"author_name":"Aaron R. Cooper","author_inst":"Octant Inc."},{"author_name":"Yi Yin","author_inst":"University of California, Los Angeles"},{"author_name":"Lior Pachter","author_inst":"California Institute of Technology"},{"author_name":"Omai B. Garner","author_inst":"University of California, Los Angeles"},{"author_name":"Jonathan Flint","author_inst":"University of California, Los Angeles"},{"author_name":"Eleazar Eskin","author_inst":"University of California, Los Angeles"},{"author_name":"Chongyuan Luo","author_inst":"University of California, Los Angeles"},{"author_name":"Sriram Kosuri","author_inst":"Octant Inc."},{"author_name":"Leonid Kruglyak","author_inst":"University of California, Los Angeles"},{"author_name":"Valerie A. Arboleda","author_inst":"University of California, Los Angeles"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.04.20168468","rel_title":"Extended lifetime of respiratory droplets in a turbulent vapour puff and its implications on airborne disease transmission","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.04.20168468","rel_abs":"To mitigate the COVID-19 pandemic, it is key to slow down the spreading of the life-threatening coronavirus (SARS-CoV-2). This spreading mainly occurs through virus-laden droplets expelled at speaking, screaming, shouting, singing, coughing, sneezing, or even breathing [1-7]. To reduce infections through such respiratory droplets, authorities all over the world have introduced the so-called \"2-meter distance rule\" or \"6-foot rule\". However, there is increasing empirical evidence, e.g. through the analysis of super-spreading events [6, 8-11], that airborne transmission of the coronavirus over much larger distances plays a major role [1-3, 7, 12-15], with tremendous implications for the risk assessment of coronavirus transmission. It is key to better and fundamentally understand the environmental ambient conditions under which airborne transmission of the coronavirus is likely to occur, in order to be able to control and adapt them. Here we employ direct numerical simulations of a typical respiratory aerosol in a turbulent jet of the respiratory event within a Lagrangian-Eulerian approach [16-18] with 5000 droplets, coupled to the ambient velocity, temperature, and humidity fields to allow for exchange of mass and heat [19] and to realistically account for the droplet evaporation under different ambient conditions. We found that for an ambient relative humidity of 50% the lifetime of the smallest droplets of our study with initial diameter of 10 m gets extended by a factor of more than 30 as compared to what is suggested by the classical picture of Wells [20, 21], due to collective effects during droplet evaporation and the role of the respiratory humidity [22], while the larger droplets basically behave ballistically. With increasing ambient relative humidity the extension of the lifetimes of the small droplets further increases and goes up to 150 times for 90% relative humidity, implying more than two meters advection range of the respiratory droplets within one second. Smaller droplets live even longer and travel further. Our results may explain why COVID-19 superspreading events can occur for large ambient relative humidity such as in cooled-down meat-processing plants [10] or in pubs with poor ventilation. We anticipate our tool and approach to be starting points for larger parameter studies and for optimizing ventilation and indoor humidity controlling concepts, which in the upcoming autumn and winter both will be key in mitigating the COVID-19 pandemic.","rel_num_authors":6,"rel_authors":[{"author_name":"Kai Leong Chong","author_inst":"University of Twente, Enschede, Netherlands"},{"author_name":"Chong Shen Ng","author_inst":"University of Twente, Enschede, Netherlands"},{"author_name":"Naoki Hori","author_inst":"University of Twente, Enschede, Netherlands"},{"author_name":"Rui Yang","author_inst":"University of Twente, Enschede, Netherlands"},{"author_name":"Roberto Verzicco","author_inst":"University of Rome 'Tor Vergata', Roma, Italy"},{"author_name":"Detlef Lohse","author_inst":"University of Twente, Enschede, Netherlands"},{"author_name":"Lynn Daboul","author_inst":"Cleveland Clinic Lerner College of Medicine of Case Western Reserve University"},{"author_name":"Michael B Rothberg","author_inst":"Cleveland Clinic"},{"author_name":"Longhua Guo","author_inst":"University of California, Los Angeles"},{"author_name":"James Boocock","author_inst":"University of California, Los Angeles"},{"author_name":"Scott W. Simpkins","author_inst":"Octant Inc."},{"author_name":"Isabella Lin","author_inst":"University of California, Los Angeles"},{"author_name":"Nathan LaPierre","author_inst":"University of California, Los Angeles"},{"author_name":"Duke Hong","author_inst":"University of California, Los Angeles"},{"author_name":"Yi Zhang","author_inst":"University of California, Los Angeles"},{"author_name":"Gabriel Oland","author_inst":"University of California Los Angeles"},{"author_name":"Bianca Judy Choe","author_inst":"University of California, Los Angeles"},{"author_name":"Sukantha Chandrasekaran","author_inst":"University of California, Los Angeles"},{"author_name":"Evann E. Hilt","author_inst":"University of California, Los Angeles"},{"author_name":"Manish J. Butte","author_inst":"University of California, Los Angeles"},{"author_name":"Robert Damoiseaux","author_inst":"University of California, Los Angeles"},{"author_name":"Aaron R. Cooper","author_inst":"Octant Inc."},{"author_name":"Yi Yin","author_inst":"University of California, Los Angeles"},{"author_name":"Lior Pachter","author_inst":"California Institute of Technology"},{"author_name":"Omai B. Garner","author_inst":"University of California, Los Angeles"},{"author_name":"Jonathan Flint","author_inst":"University of California, Los Angeles"},{"author_name":"Eleazar Eskin","author_inst":"University of California, Los Angeles"},{"author_name":"Chongyuan Luo","author_inst":"University of California, Los Angeles"},{"author_name":"Sriram Kosuri","author_inst":"Octant Inc."},{"author_name":"Leonid Kruglyak","author_inst":"University of California, Los Angeles"},{"author_name":"Valerie A. Arboleda","author_inst":"University of California, Los Angeles"}],"version":"1","license":"cc_by","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.04.20168351","rel_title":"Estimation of Effective Reproduction Number for COVID-19 in Bangladesh and its districts","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.04.20168351","rel_abs":"Background Bangladesh is going through an unprecedented crisis since the onset of the COVID-19 pandemic. Throughout the COVID-19 pandemic, the reproduction number of COVID-19 swarmed in the scientific community and public media due to its simplicity in explaining an infectious disease dynamic. This paper aims to estimate the effective reproduction number (Rt) for COVID-19 over time in Bangladesh and its districts using reported cases. Methods Adapted methods derived from Bettencourt and Ribeiro (2008), which is a sequential Bayesian approach using the compartmental Susceptible-Infectious-Recovered (SIR) model, have been used to estimate Rt. Findings As of July 21, the mean Rt is 1.32(0.98-1.70, 90% HDI), with a median of 1.16(0.99-1.34 90% HDI). The initial Rt of Bangladesh was 3, whereas the Rt on the day of imposing nation-wide lockdown was 1.47, at the end of lockdown phase 1 was 1.06, at the end of lockdown phase 2 was 1.33. Each phase of nation-wide lockdown has contributed to the decline of effective reproduction number (Rt) for Bangladesh by 28.44%, and 26.70%, respectively, implying moderate effectiveness of the epidemic response strategies. Interpretation and Conclusion The mean Rt fell by 13.55% from May 31 to July 21, 2020, despite easing of lockdown in Bangladesh. The Rt continued to fall below the threshold value one steadily from the beginning of July and sustained around 1. The mean Rt fell by 13.55% from May 31 to July 21, 2020, despite easing of lockdown in Bangladesh. As of July 21, the current estimate of Rt is 1.07(0.92-1.15: 90% HDI), meaning that an infected individual is spreading the virus to an average of one other, with 0.07 added chance of infecting a second individual. This whole research recommends two things- broader testing and careful calibration of measures to keep Rt a long way below the crucial threshold one.","rel_num_authors":8,"rel_authors":[{"author_name":"Al-Ekram Elahee Hridoy","author_inst":"Department of Geography and Environmental Studies, University of Chittagong"},{"author_name":"Mohammad Naim","author_inst":"Department of Electrical and Computer Engineering, North South University"},{"author_name":"Edris Alam","author_inst":"Integrated Emergency Management and Business Continue Program, Rabdan Academy"},{"author_name":"Nazim Uddin Emon","author_inst":"Department of Pharmacy, International Islamic University Chittagong"},{"author_name":"Imrul Hasan Tipo","author_inst":"Department of Biochemistry and Molecular Biology, University of Chittagong"},{"author_name":"Shekh Md. Shajid Hasan Tusher","author_inst":"Department of Geography and Environmental Studies, University of Chittagong"},{"author_name":"Safaet Alam","author_inst":"Department of Pharmaceutical Chemistry, University of Dhaka"},{"author_name":"Mohammad Safiqul Islam","author_inst":"Noakhali Science and Technology University"},{"author_name":"Longhua Guo","author_inst":"University of California, Los Angeles"},{"author_name":"James Boocock","author_inst":"University of California, Los Angeles"},{"author_name":"Scott W. Simpkins","author_inst":"Octant Inc."},{"author_name":"Isabella Lin","author_inst":"University of California, Los Angeles"},{"author_name":"Nathan LaPierre","author_inst":"University of California, Los Angeles"},{"author_name":"Duke Hong","author_inst":"University of California, Los Angeles"},{"author_name":"Yi Zhang","author_inst":"University of California, Los Angeles"},{"author_name":"Gabriel Oland","author_inst":"University of California Los Angeles"},{"author_name":"Bianca Judy Choe","author_inst":"University of California, Los Angeles"},{"author_name":"Sukantha Chandrasekaran","author_inst":"University of California, Los Angeles"},{"author_name":"Evann E. Hilt","author_inst":"University of California, Los Angeles"},{"author_name":"Manish J. Butte","author_inst":"University of California, Los Angeles"},{"author_name":"Robert Damoiseaux","author_inst":"University of California, Los Angeles"},{"author_name":"Aaron R. Cooper","author_inst":"Octant Inc."},{"author_name":"Yi Yin","author_inst":"University of California, Los Angeles"},{"author_name":"Lior Pachter","author_inst":"California Institute of Technology"},{"author_name":"Omai B. Garner","author_inst":"University of California, Los Angeles"},{"author_name":"Jonathan Flint","author_inst":"University of California, Los Angeles"},{"author_name":"Eleazar Eskin","author_inst":"University of California, Los Angeles"},{"author_name":"Chongyuan Luo","author_inst":"University of California, Los Angeles"},{"author_name":"Sriram Kosuri","author_inst":"Octant Inc."},{"author_name":"Leonid Kruglyak","author_inst":"University of California, Los Angeles"},{"author_name":"Valerie A. Arboleda","author_inst":"University of California, Los Angeles"}],"version":"1","license":"cc_by_nc","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.05.239046","rel_title":"Phylogenetic analysis of SARS-CoV-2 data is difficult","rel_date":"2020-08-06","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.08.05.239046","rel_abs":"Numerous studies covering some aspects of SARS-CoV-2 data analyses are being published on a daily basis, including a regularly updated phylogeny on nextstrain.org. Here, we review the difficulties of inferring reliable phylogenies by example of a data snapshot comprising all virus sequences available on May 5, 2020 from gisaid.org. We find that it is difficult to infer a reliable phylogeny on these data due to the large number of sequences in conjunction with the low number of mutations. We further find that rooting the inferred phylogeny with some degree of confidence either via the bat and pangolin outgroups or by applying novel computational methods on the ingroup phylogeny does not appear to be possible. Finally, an automatic classification of the current sequences into sub-classes based on statistical criteria is also not possible, as the sequences are too closely related. We conclude that, although the application of phylogenetic methods to disentangle the evolution and spread of COVID-19 provides some insight, results of phylogenetic analyses, in particular those conducted under the default settings of current phylogenetic inference tools, as well as downstream analyses on the inferred phylogenies, should be considered and interpreted with extreme caution.","rel_num_authors":13,"rel_authors":[{"author_name":"Benoit Morel","author_inst":"Heidelberg Institute for Theoretical Studies gGmbH"},{"author_name":"Pierre Barbera","author_inst":"Heidelberg Institute for Theoretical Studies"},{"author_name":"Lucas Czech","author_inst":"Department of Plant Biology, Carnegie Institution for Science, Stanford, CA, USA"},{"author_name":"Ben Bettisworth","author_inst":"Heidelberg Institute for Theoretical Studies"},{"author_name":"Lukas Huebner","author_inst":"Heidelberg Institute for Theoretical Studies gGmbH"},{"author_name":"Sarah Lutteropp","author_inst":"Heidelberg Institute for Theoretical Studies"},{"author_name":"Dora Serdari","author_inst":"Heidelberg Institute for Theoretical Studies gGmbH"},{"author_name":"Evangelia-Georgia Kostaki","author_inst":"Department of Hygiene Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"},{"author_name":"Ioannis Mamais","author_inst":"Department of Health Sciences, European University Cyprus, Nicosia-Cyprus"},{"author_name":"Alexey Kozlov","author_inst":"Heidelberg Institute for Theoretical Studies gGmbH"},{"author_name":"Pavlos M Pavlidis","author_inst":"Foundation for Research and Technology, Hellas"},{"author_name":"Dimitrios Paraskevis","author_inst":"National and Kapoditrian University of Athens, Medical School"},{"author_name":"Alexandros Stamatakis","author_inst":"HITS gGmbH"},{"author_name":"Duke Hong","author_inst":"University of California, Los Angeles"},{"author_name":"Yi Zhang","author_inst":"University of California, Los Angeles"},{"author_name":"Gabriel Oland","author_inst":"University of California Los Angeles"},{"author_name":"Bianca Judy Choe","author_inst":"University of California, Los Angeles"},{"author_name":"Sukantha Chandrasekaran","author_inst":"University of California, Los Angeles"},{"author_name":"Evann E. Hilt","author_inst":"University of California, Los Angeles"},{"author_name":"Manish J. Butte","author_inst":"University of California, Los Angeles"},{"author_name":"Robert Damoiseaux","author_inst":"University of California, Los Angeles"},{"author_name":"Aaron R. Cooper","author_inst":"Octant Inc."},{"author_name":"Yi Yin","author_inst":"University of California, Los Angeles"},{"author_name":"Lior Pachter","author_inst":"California Institute of Technology"},{"author_name":"Omai B. Garner","author_inst":"University of California, Los Angeles"},{"author_name":"Jonathan Flint","author_inst":"University of California, Los Angeles"},{"author_name":"Eleazar Eskin","author_inst":"University of California, Los Angeles"},{"author_name":"Chongyuan Luo","author_inst":"University of California, Los Angeles"},{"author_name":"Sriram Kosuri","author_inst":"Octant Inc."},{"author_name":"Leonid Kruglyak","author_inst":"University of California, Los Angeles"},{"author_name":"Valerie A. Arboleda","author_inst":"University of California, Los Angeles"}],"version":"1","license":"cc_by_nc_nd","type":"new results","category":"evolutionary biology"},{"rel_doi":"10.1101\/2020.08.06.240325","rel_title":"Signatures and mechanisms of efficacious therapeutic ribonucleotides against SARS-CoV-2 revealed by analysis of its replicase using magnetic tweezers","rel_date":"2020-08-06","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.08.06.240325","rel_abs":"Coronavirus Disease 2019 (COVID-19) results from an infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the third coronavirus outbreak to plague humanity this century. Currently, the most efficacious therapeutic against SARS-CoV-2 infection is the Remdesivir (RDV), an adenine-like ribonucleotide analogue that is very efficiently incorporated by the SARS-CoV-2 replicase. Understanding why RDV is so well incorporated will facilitate development of even more effective therapeutics. Here, we have applied a high-throughput, single-molecule, magnetic-tweezers platform to study thousands of cycles of nucleotide addition by the SARS-CoV-2 replicase in the absence and presence of RDV, a Favipiravir-related analog (T-1106), and the endogenously produced ddhCTP. Our data are consistent with two parallel catalytic pathways of the replicase: a high-fidelity catalytic (HFC) state and a low-fidelity catalytic (LFC) state, the latter allowing the slow incorporation of both cognate and non-cognate nucleotides. ddhCTP accesses HFC, T-1106 accesses LFC as a non-cognate nucleotide, while RDV efficiently accesses both LFC pathway. In contrast to previous reports, we provide unequivocal evidence against RDV functioning as a chain terminator. We show that RDV incorporation transiently stalls the replicase, only appearing as termination events when traditional, gel-based assays are used. The efficiency of ddhCTP utilization by the SARS-CoV-2 replicase suggests suppression of its synthesis during infection, inspiring new therapeutic strategies. Use of this experimental paradigm will be essential to the development of therapeutic nucleotide analogs targeting polymerases.","rel_num_authors":14,"rel_authors":[{"author_name":"Mona Seifert","author_inst":"Junior Research Group 2, Interdisciplinary Center for Clinical Research, Friedrich-Alexander-University Erlangen-Nurnberg (FAU), Cauerstr. 3, 91058 Erlangen, Ge"},{"author_name":"Subhas C. Bera","author_inst":"Junior Research Group 2, Interdisciplinary Center for Clinical Research, Friedrich-Alexander-University Erlangen-Nurnberg (FAU), Cauerstr. 3, 91058 Erlangen, Ge"},{"author_name":"Pauline van Nies","author_inst":"Junior Research Group 2, Interdisciplinary Center for Clinical Research, Friedrich-Alexander-University Erlangen-Nurnberg (FAU), Cauerstr. 3, 91058 Erlangen, Ge"},{"author_name":"Robert N. Kirchdoerfer","author_inst":"University of Wisconsin-Madison"},{"author_name":"Ashleigh Shannon","author_inst":"Architecture et Fonction des Macromolecules Biologiques, CNRS and Aix-Marseille Universite, UMR 7257, Polytech Case 925, 13009 Marseille, France."},{"author_name":"Thi-Tuyet-Nhung Le","author_inst":"Architecture et Fonction des Macromolecules Biologiques, CNRS and Aix-Marseille Universite, UMR 7257, Polytech Case 925, 13009 Marseille, France."},{"author_name":"Tyler L. Grove","author_inst":"Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY, USA Institute for Protein Innovation, Boston, MA, USA"},{"author_name":"Flavia S. Papini","author_inst":"Junior Research Group 2, Interdisciplinary Center for Clinical Research, Friedrich-Alexander-University Erlangen-Nurnberg (FAU), Cauerstr. 3, 91058 Erlangen, Ge"},{"author_name":"Jamie J. Arnold","author_inst":"Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC 27514 USA"},{"author_name":"Steven C. Almo","author_inst":"Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY, USA Institute for Protein Innovation, Boston, MA, USA"},{"author_name":"Bruno Canard","author_inst":"Architecture et Fonction des Macromolecules Biologiques, CNRS and Aix-Marseille Universite, UMR 7257, Polytech Case 925, 13009 Marseille, France."},{"author_name":"Martin Depken","author_inst":"Department of Bionanoscience, Kavli Institute of Nanoscience, Delft University of Technology, Van der Maasweg 9, 2629 HZ Delft, The Netherlands"},{"author_name":"Craig E. Cameron","author_inst":"Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC 27514 USA"},{"author_name":"David Dulin","author_inst":"Junior Research Group 2, Interdisciplinary Center for Clinical Research, Friedrich-Alexander-University Erlangen-Nurnberg (FAU), Cauerstr. 3, 91058 Erlangen, Ge"},{"author_name":"Yi Zhang","author_inst":"University of California, Los Angeles"},{"author_name":"Gabriel Oland","author_inst":"University of California Los Angeles"},{"author_name":"Bianca Judy Choe","author_inst":"University of California, Los Angeles"},{"author_name":"Sukantha Chandrasekaran","author_inst":"University of California, Los Angeles"},{"author_name":"Evann E. Hilt","author_inst":"University of California, Los Angeles"},{"author_name":"Manish J. Butte","author_inst":"University of California, Los Angeles"},{"author_name":"Robert Damoiseaux","author_inst":"University of California, Los Angeles"},{"author_name":"Aaron R. Cooper","author_inst":"Octant Inc."},{"author_name":"Yi Yin","author_inst":"University of California, Los Angeles"},{"author_name":"Lior Pachter","author_inst":"California Institute of Technology"},{"author_name":"Omai B. Garner","author_inst":"University of California, Los Angeles"},{"author_name":"Jonathan Flint","author_inst":"University of California, Los Angeles"},{"author_name":"Eleazar Eskin","author_inst":"University of California, Los Angeles"},{"author_name":"Chongyuan Luo","author_inst":"University of California, Los Angeles"},{"author_name":"Sriram Kosuri","author_inst":"Octant Inc."},{"author_name":"Leonid Kruglyak","author_inst":"University of California, Los Angeles"},{"author_name":"Valerie A. Arboleda","author_inst":"University of California, Los Angeles"}],"version":"1","license":"cc_by_nc","type":"new results","category":"biophysics"},{"rel_doi":"10.1101\/2020.08.05.20169128","rel_title":"Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.05.20169128","rel_abs":"Abstract Objectives:To investigate longitudinal trajectory of SARS-CoV-2 neutralising antibodies and the performance of serological assays in diagnosing prior infection and predicting serum neutralisation titres with time Design Retrospective longitudinal analysis of a COVID19 case cohort . Setting NHS outpatient clinics Participants Individuals with RT-PCR diagnosed SARS-CoV-2 infection that did not require hospitalization Main outcome measures The sensitivity with which prior infection was detected and quantitative antibody titres were assessed using four SARS-CoV-2 serologic assay platforms. Two platforms employed SARS-CoV-2 spike (S) based antigens and two employed nucleocapsid (N) based antigens. Serum neutralising antibody titres were measured using a validated pseudotyped virus SARS-CoV-2 neutralisation assay. The ability of the serological assays to predict neutralisation titres at various times after PCR diagnosis was assessed. Results The three of the four serological assays had sensitivities of 95 to100% at 21-40 days post PCR-diagnosis, while a fourth assay had a lower sensitivity of 85%. The relative sensitivities of the assays changed with time and the sensitivity of one assay that had an initial sensitivity of >95% declined to 85% at 61-80 post PCR diagnosis, and to 71% at 81-100 days post diagnosis. Median antibody titres decreased in one serologic assay but were maintained over the observation period in other assays. The trajectories of median antibody titres measured in serologic assays over this time period were not dependent on whether the SARS-CoV-2 N or S proteins were used as antigen source. A broad range of SARS-CoV-2 neutralising titres were evident in individual sera, that decreased over time in the majority of participants; the median neutralisation titre in the cohort decreased by 45% over 4 weeks. Each of the serological assays gave quantitative measurements of antibody titres that correlated with SARS-CoV-2 neutralisation titres, but, the S-based serological assay measurements better predicted serum neutralisation potency. The strength of correlation between serologic assay results and neutralisation titres deteriorated with time and decreases in neutralisation titres in individual participants were not well predicted by changes in antibody titres measured using serologic assays. Conclusions: SARS-CoV-2 serologic assays differed in their comparative diagnostic performance over time. Different assays are more or less well suited for surveillance of populations for prior infection versus prediction of serum neutralisation potency. Continued monitoring of declining neutralisation titres during extended follow up should facilitate the establishment of appropriate serologic correlates of protection against SARS-CoV-2 reinfection.","rel_num_authors":16,"rel_authors":[{"author_name":"Frauke Muecksch","author_inst":"Laboratory of Retrovirology, The Rockefeller University, 1230 York Avenue, New York NY 10065"},{"author_name":"Helen Wise","author_inst":"Royal Infirmary of Edinburgh, NHS Lothian, 51 Little France Crescent, Edinburgh EH16 4SA"},{"author_name":"Becky Batchelor","author_inst":"Royal Infirmary of Edinburgh, NHS Lothian, 51 Little France Crescent, Edinburgh EH16 4SA"},{"author_name":"Maria Squires","author_inst":"Royal Infirmary of Edinburgh, NHS Lothian, 51 Little France Crescent, Edinburgh EH16 4SA"},{"author_name":"Elizabeth Semple","author_inst":"Royal Infirmary of Edinburgh, NHS Lothian, 51 Little France Crescent, Edinburgh EH16 4SA"},{"author_name":"Claire Richardson","author_inst":"University Hospital Monklands, NHS Lanarkshire, Airdrie ML6 0JS"},{"author_name":"Jacqueline McGuire","author_inst":"University Hospital Monklands, NHS Lanarkshire, Airdrie ML6 0JS"},{"author_name":"Sarah Cleary","author_inst":"University Hospital Monklands, NHS Lanarkshire, Airdrie ML6 0JS"},{"author_name":"Elizabeth Furrie","author_inst":"Ninewells Hospital and Medical School, NHS Tayside, Dundee DD1 9SY"},{"author_name":"Neil Greig","author_inst":"Ninewells Hospital and Medical School, NHS Tayside, Dundee DD1 9SY"},{"author_name":"Gordon Hay","author_inst":"Ninewells Hospital and Medical School, NHS Tayside, Dundee DD1 9SY"},{"author_name":"Kate Templeton","author_inst":"Royal Infirmary of Edinburgh, NHS Lothian, 51 Little France Crescent, Edinburgh EH16 4SA"},{"author_name":"Julio C.C. Lorenzi","author_inst":"Laboratory of Molecular Immunology, The Rockefeller University, 1230 York Avenue, New York NY 10065"},{"author_name":"Theodora Hatziioannou","author_inst":"Laboratory of Retrovirology, The Rockefeller University, 1230 York Avenue, New York NY 10065"},{"author_name":"Sara J Jenks","author_inst":"NHS Lothian"},{"author_name":"Paul Bieniasz","author_inst":"Laboratory of Retrovirology, The Rockefeller University, 1230 York Avenue, New York NY 10065"},{"author_name":"Bianca Judy Choe","author_inst":"University of California, Los Angeles"},{"author_name":"Sukantha Chandrasekaran","author_inst":"University of California, Los Angeles"},{"author_name":"Evann E. Hilt","author_inst":"University of California, Los Angeles"},{"author_name":"Manish J. Butte","author_inst":"University of California, Los Angeles"},{"author_name":"Robert Damoiseaux","author_inst":"University of California, Los Angeles"},{"author_name":"Aaron R. Cooper","author_inst":"Octant Inc."},{"author_name":"Yi Yin","author_inst":"University of California, Los Angeles"},{"author_name":"Lior Pachter","author_inst":"California Institute of Technology"},{"author_name":"Omai B. Garner","author_inst":"University of California, Los Angeles"},{"author_name":"Jonathan Flint","author_inst":"University of California, Los Angeles"},{"author_name":"Eleazar Eskin","author_inst":"University of California, Los Angeles"},{"author_name":"Chongyuan Luo","author_inst":"University of California, Los Angeles"},{"author_name":"Sriram Kosuri","author_inst":"Octant Inc."},{"author_name":"Leonid Kruglyak","author_inst":"University of California, Los Angeles"},{"author_name":"Valerie A. Arboleda","author_inst":"University of California, Los Angeles"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.05.20169078","rel_title":"Transient dynamics of SARS-CoV-2 as England exited national lockdown","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.05.20169078","rel_abs":"Control of the COVID-19 pandemic requires a detailed understanding of prevalence of SARS-CoV-2 virus in the population. Case-based surveillance is necessarily biased towards symptomatic individuals and sensitive to varying patterns of reporting in space and time. The real-time assessment of community transmission antigen study (REACT-1) is designed to overcome these limitations by obtaining prevalence data based on a nose and throat swab RT-PCR test among a representative community-based sample in England, including asymptomatic individuals. Here, we describe results comparing rounds 1 and 2 carried out during May and mid June \/ early July 2020 respectively across 315 lower tier local authority areas. In round 1 we found 159 positive samples from 120,620 tested swabs while round 2 there were 123 positive samples from 159,199 tested swabs, indicating a downwards trend in prevalence from 0.13% (95% CI, 0.11%, 0.15%) to 0.077% (0.065%, 0.092%), a halving time of 38 (28, 58) days, and an R of 0.89 (0.86, 0.93). The proportion of swab-positive participants who were asymptomatic at the time of sampling increased from 69% (61%, 76%) in round 1 to 81% (73%, 87%) in round 2. Although health care and care home workers were infected far more frequently than other workers in round 1, the odds were markedly reduced in round 2. Age patterns of infection changed between rounds, with a reduction by a factor of five in prevalence in 18 to 24 year olds. Our data were suggestive of increased risk of infection in Black and Asian (mainly South Asian) ethnicities. Using regional and detailed case location data, we detected increased infection intensity in and near London. Under multiple sensitivity analyses, our results were robust to the possibility of false positives. At the end of the initial lockdown in England, we found continued decline in prevalence and a shift in the pattern of infection by age and occupation. Community-based sampling, including asymptomatic individuals, is necessary to fully understand the nature of ongoing transmission.","rel_num_authors":14,"rel_authors":[{"author_name":"Steven Riley","author_inst":"Dept Inf Dis Epi, Imperial College"},{"author_name":"Kylie E. C. Ainslie","author_inst":"Imperial College London"},{"author_name":"Oliver Eales","author_inst":"Imperial College London"},{"author_name":"Caroline E Walters","author_inst":"Imperial College London"},{"author_name":"Haowei Wang","author_inst":"Imperial College London"},{"author_name":"Christina J Atchison","author_inst":"Imperial College London"},{"author_name":"Peter Diggle","author_inst":"Lancaster University"},{"author_name":"Deborah Ashby","author_inst":"Imperial College London"},{"author_name":"Christl A. Donnelly","author_inst":"Imperial College London"},{"author_name":"Graham Cooke","author_inst":"Imperial College Healthcare NHS Trust"},{"author_name":"Wendy Barclay","author_inst":"Imperial College London"},{"author_name":"Helen Ward","author_inst":"Imperial College London"},{"author_name":"Ara Darzi","author_inst":"Imperial College Healthcare NHS Trust"},{"author_name":"Paul Elliott","author_inst":"Imperial College London School of Public Health"},{"author_name":"Sara J Jenks","author_inst":"NHS Lothian"},{"author_name":"Paul Bieniasz","author_inst":"Laboratory of Retrovirology, The Rockefeller University, 1230 York Avenue, New York NY 10065"},{"author_name":"Bianca Judy Choe","author_inst":"University of California, Los Angeles"},{"author_name":"Sukantha Chandrasekaran","author_inst":"University of California, Los Angeles"},{"author_name":"Evann E. Hilt","author_inst":"University of California, Los Angeles"},{"author_name":"Manish J. Butte","author_inst":"University of California, Los Angeles"},{"author_name":"Robert Damoiseaux","author_inst":"University of California, Los Angeles"},{"author_name":"Aaron R. Cooper","author_inst":"Octant Inc."},{"author_name":"Yi Yin","author_inst":"University of California, Los Angeles"},{"author_name":"Lior Pachter","author_inst":"California Institute of Technology"},{"author_name":"Omai B. Garner","author_inst":"University of California, Los Angeles"},{"author_name":"Jonathan Flint","author_inst":"University of California, Los Angeles"},{"author_name":"Eleazar Eskin","author_inst":"University of California, Los Angeles"},{"author_name":"Chongyuan Luo","author_inst":"University of California, Los Angeles"},{"author_name":"Sriram Kosuri","author_inst":"Octant Inc."},{"author_name":"Leonid Kruglyak","author_inst":"University of California, Los Angeles"},{"author_name":"Valerie A. Arboleda","author_inst":"University of California, Los Angeles"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.05.20168963","rel_title":"Repeat COVID-19 Molecular Testing: Correlation with Recovery of Infectious Virus, Molecular Assay Cycle Thresholds, and Analytical Sensitivity","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.05.20168963","rel_abs":"Repeat molecular testing for SARS-CoV-2 may result in scenarios including multiple positive results, positive test results after negative tests, and repeated false negative results in symptomatic individuals. Consecutively collected specimens from a retrospective cohort of COVID-19 patients at the Johns Hopkins Hospital were assessed for RNA and infectious virus shedding. Whole genome sequencing confirmed the virus genotype in patients with prolonged viral RNA shedding and droplet digital PCR (ddPCR) was used to assess the rate of false negative standard of care PCR results. Recovery of infectious virus was associated with Ct values of 18.8 {+\/-} 3.4. Prolonged viral RNA shedding was associated with recovery of infectious virus in specimens collected up to 20 days after the first positive result in patients who were symptomatic at the time of specimen collection. The use of Ct values and clinical symptoms provides a more accurate assessment of the potential for infectious virus shedding.","rel_num_authors":15,"rel_authors":[{"author_name":"Victoria Gniazdowski","author_inst":"Johns Hopkins University School of Medicine"},{"author_name":"C. Paul Morris","author_inst":"Johns Hopkins University School of Medicine"},{"author_name":"Shirlee Wohl","author_inst":"Johns Hopkins Bloomberg School of Public Health"},{"author_name":"Thomas Mehoke","author_inst":"Johns Hopkins University Applied Physics Laboratory"},{"author_name":"Srividya Ramakrishnan","author_inst":"Johns Hopkins University"},{"author_name":"Peter Thielen","author_inst":"Johns Hopkins University Applied Physics Laboratory"},{"author_name":"Harrison Powell","author_inst":"Johns Hopkins Bloomberg School of Public Health"},{"author_name":"Brendan D Smith","author_inst":"Johns Hopkins Bloomberg School of Public Health"},{"author_name":"Derek T Armstrong","author_inst":"Johns Hopkins University School of Medicine"},{"author_name":"Monica Herrera","author_inst":"Bio-Rad Laboratories"},{"author_name":"Carolyn Reifsnyder","author_inst":"Bio-Rad Laboratories"},{"author_name":"Maria Sevdali","author_inst":"Bio-Rad Laboratories"},{"author_name":"Karen C Carroll","author_inst":"Johns Hopkins University School of Medicine"},{"author_name":"Andrew Pekosz","author_inst":"Johns Hopkins Bloomberg School of Public Health"},{"author_name":"Heba H Mostafa","author_inst":"Johns Hopkins University School of Medicine"},{"author_name":"Paul Bieniasz","author_inst":"Laboratory of Retrovirology, The Rockefeller University, 1230 York Avenue, New York NY 10065"},{"author_name":"Bianca Judy Choe","author_inst":"University of California, Los Angeles"},{"author_name":"Sukantha Chandrasekaran","author_inst":"University of California, Los Angeles"},{"author_name":"Evann E. Hilt","author_inst":"University of California, Los Angeles"},{"author_name":"Manish J. Butte","author_inst":"University of California, Los Angeles"},{"author_name":"Robert Damoiseaux","author_inst":"University of California, Los Angeles"},{"author_name":"Aaron R. Cooper","author_inst":"Octant Inc."},{"author_name":"Yi Yin","author_inst":"University of California, Los Angeles"},{"author_name":"Lior Pachter","author_inst":"California Institute of Technology"},{"author_name":"Omai B. Garner","author_inst":"University of California, Los Angeles"},{"author_name":"Jonathan Flint","author_inst":"University of California, Los Angeles"},{"author_name":"Eleazar Eskin","author_inst":"University of California, Los Angeles"},{"author_name":"Chongyuan Luo","author_inst":"University of California, Los Angeles"},{"author_name":"Sriram Kosuri","author_inst":"Octant Inc."},{"author_name":"Leonid Kruglyak","author_inst":"University of California, Los Angeles"},{"author_name":"Valerie A. Arboleda","author_inst":"University of California, Los Angeles"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.05.20168435","rel_title":"First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.05.20168435","rel_abs":"Background NVX-CoV2373 is a recombinant nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins. We present the Day 35 primary analysis of our trial of NVX-CoV2373 with or without the saponin-based Matrix-M1 adjuvant in healthy adults. Methods This is a randomized, observer-blinded, placebo-controlled, phase 1 trial in 131 healthy adults. Trial vaccination comprised two intramuscular injections, 21 days apart. Primary outcomes were reactogenicity, safety labs, and immunoglobulin G (IgG) anti-spike protein response. Secondary outcomes included adverse events, wild-type virus neutralizing antibody, and T-cell responses. Results Participants received NVX-CoV2373 with or without Matrix-M1 (n=106) or placebo (n=25). There were no serious adverse events. Reactogenicity was mainly mild in severity and of short duration (mean [&ge;] 2 days), with second vaccinations inducing greater local and systemic reactogenicity. The adjuvant significantly enhanced immune responses and was antigen dose-sparing, and the two-dose 5g NVX-CoV2373\/Matrix-M1 vaccine induced mean anti-spike IgG and neutralizing antibody responses that exceeded the mean responses in convalescent sera from COVID-19 patients with clinically significant illnesses. The vaccine also induced antigen-specific T cells with a largely T helper 1 (Th1) phenotype. Conclusions NVX-CoV2373\/Matrix-M1 was well tolerated and elicited robust immune responses (IgG and neutralization) four-fold higher than the mean observed in COVID-19 convalescent serum from participants with clinical symptoms requiring medical care and induced CD4+ T-cell responses biased toward a Th1 phenotype. These findings suggest that the vaccine may confer protection and support transition to efficacy evaluations to test this hypothesis. (Funded by the Coalition for Epidemic Preparedness Innovations; ClinicalTrials.gov number, NCT04368988).","rel_num_authors":29,"rel_authors":[{"author_name":"Cheryl Keech","author_inst":"Novavax, Inc."},{"author_name":"Gary Albert","author_inst":"Novavax, Inc."},{"author_name":"Patricia Reed","author_inst":"Novavax, Inc."},{"author_name":"Susan Neal","author_inst":"Novavax, Inc."},{"author_name":"Joyce S. Plested","author_inst":"Novavax, Inc."},{"author_name":"Mingzhu Zhu","author_inst":"Novavax, Inc."},{"author_name":"Shane Cloney-Clark","author_inst":"Novavax, Inc."},{"author_name":"Haixia Zhou","author_inst":"Novavax, Inc."},{"author_name":"Nita Patel","author_inst":"Novavax, Inc."},{"author_name":"Matthew B. Frieman","author_inst":"University of Maryland School of Medicine"},{"author_name":"Robert E. Haupt","author_inst":"University of Maryland School of Medicine"},{"author_name":"James Logue","author_inst":"University of Maryland School of Medicine"},{"author_name":"Marisa McGrath","author_inst":"University of Maryland School of Medicine"},{"author_name":"Stuart Weston","author_inst":"University of Maryland School of Medicine"},{"author_name":"Pedro A. Piedra","author_inst":"Baylor University College of Medicine"},{"author_name":"Iksung Cho","author_inst":"Novavax, Inc."},{"author_name":"Andreana Robertson","author_inst":"Novavax, Inc."},{"author_name":"Chinar Desai","author_inst":"Novavax, Inc."},{"author_name":"Kathleen Callahan","author_inst":"Novavax, Inc."},{"author_name":"Maggie Lewis","author_inst":"Novavax, Inc."},{"author_name":"Patricia Price-Abbott","author_inst":"Novavax, Inc."},{"author_name":"Neil Formica","author_inst":"Novavax, Inc."},{"author_name":"Vivek Shinde","author_inst":"Novavax, Inc."},{"author_name":"Louis Fries","author_inst":"Novavax, Inc."},{"author_name":"Jason D. Linkliter","author_inst":"Nucleus Network Pty Ltd"},{"author_name":"Paul Griffin","author_inst":"Q-Pharm"},{"author_name":"Bethanie Wilkinson","author_inst":"Novavax, Inc."},{"author_name":"Gale Smith","author_inst":"Novavax, Inc."},{"author_name":"Gregory M. Glenn","author_inst":"Novavax, Inc."},{"author_name":"Leonid Kruglyak","author_inst":"University of California, Los Angeles"},{"author_name":"Valerie A. Arboleda","author_inst":"University of California, Los Angeles"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.05.20168872","rel_title":"Inflammasome activation in COVID-19 patients","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.05.20168872","rel_abs":"Severe cases of COVID-19 are characterized by a strong inflammatory process that may ultimately lead to organ failure and patient death. The NLRP3 inflammasome is a molecular platform that promotes inflammation via cleavage and activation of key inflammatory molecules including active caspase-1 (Casp1p20), IL-1{beta} and IL-18. Although the participation of the inflammasome in COVID-19 has been highly speculated, the inflammasome activation and participation in the outcome of the disease is unknown. Here we demonstrate that the NLRP3 inflammasome is activated in response to SARS-CoV-2 infection and it is active in COVID-19, influencing the clinical outcome of the disease. Studying moderate and severe COVID-19 patients, we found active NLRP3 inflammasome in PBMCs and tissues of post-mortem patients upon autopsy. Inflammasome-derived products such as Casp1p20 and IL-18 in the sera correlated with the markers of COVID-19 severity, including IL-6 and LDH. Moreover, higher levels of IL-18 and Casp1p20 are associated with disease severity and poor clinical outcome. Our results suggest that the inflammasome is key in the pathophysiology of the disease, indicating this platform as a marker of disease severity and a potential therapeutic target for COVID-19.","rel_num_authors":45,"rel_authors":[{"author_name":"Tamara S Rodrigues","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Keyla SG Sa","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Adriene Y Ishimoto","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Amanda Becerra","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Samuel Oliveira","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Leticia Almeida","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Augusto V Goncalves","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Debora B Perucello","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Warrison A Andrade","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Ricardo Castro","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Flavio P Veras","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Juliana E Toller-Kawahisa","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Daniele C Nascimento","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Mikhael HF de Lima","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Camila MS Silva","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Diego B Caetite","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Ronaldo B Martins","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Italo A Castro","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Marjorie C Pontelli","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabio C de Barros","author_inst":"Departamento de Ecologia e Biologia Evolutiva, Instituto de Ciencias Ambientais, Quimicas e Farmaceuticas, Universidade Federal de Sao Paulo"},{"author_name":"Natalia B do Amaral","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Marcela C Giannini","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Leticia P Bonjorno","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Isabel F Lopes","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maira N Benatti","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Rodrigo C Santana","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fernando C Vilar","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Auxiliadora-Martins","author_inst":"Divisao de Medicina Intensiva, Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rodrigo Luppino-Assad","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sergio CL de Almeida","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fabiola R de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sabrina S Batah","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Li Siyuan","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Maira N Benatti","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Thiago M Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Jose C Alves-Filho","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fernando Q Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Larissa D Cunha","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabiani G Frantz","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Tiana Kohlsdorf","author_inst":"Departamento de Biologia, Faculdade de Filosofia Ciencias e Letras de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Alexandre T Fabro","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Eurico Arruda","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rene DR de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Paulo Louzada-Junior","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Dario S Zamboni","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.05.20169086","rel_title":"An Examination of School Reopening Strategies during the SARS-CoV-2 Pandemic","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.05.20169086","rel_abs":"The SARS-CoV-2 pandemic led to the closure of nearly all K-12 schools in the United States of America in March 2020. Although reopening K-12 schools for in-person schooling is desirable for many reasons, officials also understand that risk reduction strategies and detection of cases must be in place to allow children to safely return to school. Furthermore, the consequences of reclosing recently reopened schools are substantial and impact teachers, parents, and ultimately the educational experience in children. Using a stratified Susceptible-Exposed-Infected-Removed model, we explore the influences of reduced class density, transmission mitigation (such as the use of masks, desk shields, frequent surface cleaning, or outdoor instruction), and viral detection on cumulative prevalence. Our model predicts that a combination of all three approaches will substantially reduce SARS-CoV-2 prevalence. The model also shows that reduction of class density and the implementation of rapid viral testing, even with imperfect detection, have greater impact than moderate measures for transmission mitigation.","rel_num_authors":7,"rel_authors":[{"author_name":"Alfonso Landeros","author_inst":"University of California, Los Angeles"},{"author_name":"Xiang Ji","author_inst":"Tulane University"},{"author_name":"Kenneth L. Lange","author_inst":"University of California, Los Angeles"},{"author_name":"Timothy C. Stutz","author_inst":"University of California, Los Angeles"},{"author_name":"Jason Xu","author_inst":"Duke University"},{"author_name":"Mary E. Sehl","author_inst":"University of California, Los Angeles"},{"author_name":"Janet S. Sinsheimer","author_inst":"University of California, Los Angeles"},{"author_name":"Debora B Perucello","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Warrison A Andrade","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Ricardo Castro","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Flavio P Veras","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Juliana E Toller-Kawahisa","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Daniele C Nascimento","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Mikhael HF de Lima","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Camila MS Silva","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Diego B Caetite","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Ronaldo B Martins","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Italo A Castro","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Marjorie C Pontelli","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabio C de Barros","author_inst":"Departamento de Ecologia e Biologia Evolutiva, Instituto de Ciencias Ambientais, Quimicas e Farmaceuticas, Universidade Federal de Sao Paulo"},{"author_name":"Natalia B do Amaral","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Marcela C Giannini","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Leticia P Bonjorno","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Isabel F Lopes","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maira N Benatti","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Rodrigo C Santana","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fernando C Vilar","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Auxiliadora-Martins","author_inst":"Divisao de Medicina Intensiva, Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rodrigo Luppino-Assad","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sergio CL de Almeida","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fabiola R de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sabrina S Batah","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Li Siyuan","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Maira N Benatti","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Thiago M Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Jose C Alves-Filho","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fernando Q Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Larissa D Cunha","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabiani G Frantz","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Tiana Kohlsdorf","author_inst":"Departamento de Biologia, Faculdade de Filosofia Ciencias e Letras de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Alexandre T Fabro","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Eurico Arruda","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rene DR de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Paulo Louzada-Junior","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Dario S Zamboni","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."}],"version":"1","license":"cc_by","type":"PUBLISHAHEADOFPRINT","category":"epidemiology"},{"rel_doi":"10.1101\/2020.08.05.20169094","rel_title":"U.S. Field Hospitals: A Study on Public Health Emergency Response to COVID-19","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.05.20169094","rel_abs":"With the number of confirmed COVID-19 cases rapidly growing in the U.S., many states are experiencing a shortage of hospital-especially ICU-beds. In addition to discharging non-critical patients, expanding local hospitals' capacity as well as re-opening closed healthcare facilities, these states are actively building or converting public venues into field hospitals to fill the gap1. By studying these makeshift hospitals, we found that the states most severely impacted by the pandemic are fast at responding with the first wave of hospitals opening around the date of peak demand and the majority ready to use by the end of April. However, depending on the types of patients the field hospitals accept (COVID-19 vs. non-COVID-19) and how they are incorporated to local healthcare system, these field hospitals have utilization rate ranging from 100% to 0%. The field hospitals acting as alternative site to treat non-COVID-19 patients typically had low utilization rate and often faced the risk of COVID-19 outbreak in the facility. As overflow facilities, the field hospitals providing intensive care were highly relied on by local healthcare systems whereas the field hospitals dedicated to patients with mild symptoms often found it hard to fill the beds due to a combination of factors such as strict regulation on transferring patients from local hospitals, complication of health insurance discouraging health-seeking behavior, and effective public health measure to \"flatten the curve\" so that the additional beds were no longer needed.","rel_num_authors":4,"rel_authors":[{"author_name":"Luorongxin Yuan","author_inst":"Department of Biology, Johns Hopkins University"},{"author_name":"Sherryn Sherryn","author_inst":"International Health, Johns Hopkins Bloomberg School of Public Health"},{"author_name":"Peter Hu","author_inst":"Department Of Anesthesiology, University of Maryland, School of Medicine"},{"author_name":"Fenghao Chen","author_inst":"The Hopkins Club for Innovation and Entrepreneurship"},{"author_name":"Jason Xu","author_inst":"Duke University"},{"author_name":"Mary E. Sehl","author_inst":"University of California, Los Angeles"},{"author_name":"Janet S. Sinsheimer","author_inst":"University of California, Los Angeles"},{"author_name":"Debora B Perucello","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Warrison A Andrade","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Ricardo Castro","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Flavio P Veras","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Juliana E Toller-Kawahisa","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Daniele C Nascimento","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Mikhael HF de Lima","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Camila MS Silva","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Diego B Caetite","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Ronaldo B Martins","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Italo A Castro","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Marjorie C Pontelli","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabio C de Barros","author_inst":"Departamento de Ecologia e Biologia Evolutiva, Instituto de Ciencias Ambientais, Quimicas e Farmaceuticas, Universidade Federal de Sao Paulo"},{"author_name":"Natalia B do Amaral","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Marcela C Giannini","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Leticia P Bonjorno","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Isabel F Lopes","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maira N Benatti","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Rodrigo C Santana","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fernando C Vilar","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Auxiliadora-Martins","author_inst":"Divisao de Medicina Intensiva, Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rodrigo Luppino-Assad","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sergio CL de Almeida","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fabiola R de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sabrina S Batah","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Li Siyuan","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Maira N Benatti","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Thiago M Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Jose C Alves-Filho","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fernando Q Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Larissa D Cunha","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabiani G Frantz","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Tiana Kohlsdorf","author_inst":"Departamento de Biologia, Faculdade de Filosofia Ciencias e Letras de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Alexandre T Fabro","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Eurico Arruda","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rene DR de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Paulo Louzada-Junior","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Dario S Zamboni","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"health systems and quality improvement"},{"rel_doi":"10.1101\/2020.08.05.20157768","rel_title":"Health systems trust in the time of Covid-19 pandemic in Bangladesh: A qualitative exploration","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.05.20157768","rel_abs":"Background: Lack of trust hinders care seeking, and limits community support for contact tracing, care seeking, information and communication uptake, multisectoral or multi-stakeholder engagement, and community participation. We aimed at exploring how trust might be breached and what implications this may have in COVID-19 pandemic response by the Bangladesh health systems. Methods: We conducted this qualitative research during the pandemic, through seven online focus group discussions, with purposively selected mixed-gender groups of clinicians and non-clinicians (n=50). Data were analyzed through conventional content analysis method. Results: The common thread throughout the findings was the pervasive mistrust of the people in Bangladeshi health systems in its management of COVID-19 pandemic. In addition to the existing health systems weaknesses, few others became evident throughout the progression of the pandemic, namely, the lack of coordination challenges during the preparatory phase as well as the advanced stages of the pandemic. This; compounded by the health systems and political leadership failures, lead to opportunistic corruption and lack of regulations; leading to low quality, discriminatory, or no service at all. These have trust implications, manifested in health seeking from unqualified providers, non-adherence to health advice, tension between the service seekers and providers, disapproval of the governance mechanism, misuse of already scarce resources, disinterest in community participation, and eventually loss of life and economy. Conclusions: Health sector stewards should learn the lessons from other countries, ensure multisectoral engagement involving the community and political forces, and empower the public health experts to organize and consolidate a concerted health systems effort in gaining trust in the short run, and building a resilient and responsive health system in the long.","rel_num_authors":3,"rel_authors":[{"author_name":"Taufique Joarder","author_inst":"Public Health Foundation, Bangladesh"},{"author_name":"Muhammad Nahian Bin Khaled","author_inst":"International Food Policy Research Institution (IFPRI)"},{"author_name":"Shahaduz Zaman","author_inst":"Medical Anthropology and Global Health (Global Health and Infection), Brighton and Sussex Medical School, University of Sussex, UK"},{"author_name":"Fenghao Chen","author_inst":"The Hopkins Club for Innovation and Entrepreneurship"},{"author_name":"Jason Xu","author_inst":"Duke University"},{"author_name":"Mary E. Sehl","author_inst":"University of California, Los Angeles"},{"author_name":"Janet S. Sinsheimer","author_inst":"University of California, Los Angeles"},{"author_name":"Debora B Perucello","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Warrison A Andrade","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Ricardo Castro","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Flavio P Veras","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Juliana E Toller-Kawahisa","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Daniele C Nascimento","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Mikhael HF de Lima","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Camila MS Silva","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Diego B Caetite","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Ronaldo B Martins","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Italo A Castro","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Marjorie C Pontelli","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabio C de Barros","author_inst":"Departamento de Ecologia e Biologia Evolutiva, Instituto de Ciencias Ambientais, Quimicas e Farmaceuticas, Universidade Federal de Sao Paulo"},{"author_name":"Natalia B do Amaral","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Marcela C Giannini","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Leticia P Bonjorno","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Isabel F Lopes","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maira N Benatti","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Rodrigo C Santana","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fernando C Vilar","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Auxiliadora-Martins","author_inst":"Divisao de Medicina Intensiva, Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rodrigo Luppino-Assad","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sergio CL de Almeida","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fabiola R de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sabrina S Batah","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Li Siyuan","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Maira N Benatti","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Thiago M Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Jose C Alves-Filho","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fernando Q Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Larissa D Cunha","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabiani G Frantz","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Tiana Kohlsdorf","author_inst":"Departamento de Biologia, Faculdade de Filosofia Ciencias e Letras de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Alexandre T Fabro","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Eurico Arruda","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rene DR de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Paulo Louzada-Junior","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Dario S Zamboni","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"health policy"},{"rel_doi":"10.1101\/2020.08.05.20169037","rel_title":"Analysis of SIR-Network Model on COVID-19 with respect to its impact on West Bengal in India","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.05.20169037","rel_abs":"The recent global pandemic of SARS-CoV-2 (COVID-19) disease has prompted many researchers to formulate lock-down and quarantine scenarios while the main concern of the researchers is to model the spread and the possible duration of the COVID-19 infections and also research on how long this is going to last. It seems that most of the researchers have recognized lock-down as one of the major impact factors in their models. As a result of this in the absence of lock-down the models formulated would not contribute much significant results. Hence, in this work we decide to formulate a mathematical model which would be able to predict the spread and also the possible duration of the pandemic, by considering both partial lock-down and the corresponding unlocking situations. Employing SIR-network models and taking the various districts of highly populated areas of West Bengal, India as the nodes or vertices we attempt to model the spread and duration of the pandemic during both partial lock-down and unlock phases but separately. We consider the populations where the locally present people and the people who have undergone migration of some shorts are well mixed together. In the network that we have provided the pointed edges refer to the migrating workers that is those that move away from their regular habitats in want of work. We use this research to study not only the trends that are associated with COVID-19 outbreaks, but also to study the impacts of the Government policies and the improvisation of medical facilities on this outbreak in West Bengal. At the end, we attempt to throw light upon the crisis that the economy of the state may have to go through separately on partial lock-down and unlocking scenarios.","rel_num_authors":5,"rel_authors":[{"author_name":"Debnarayan Khatua","author_inst":"Global Institute of Science and Technology"},{"author_name":"Debashree Guha","author_inst":"IIT Kharagpur, India"},{"author_name":"Samarjit Kar","author_inst":"NIT Durgapur, India"},{"author_name":"Anupam De","author_inst":"Haldia Institute of Technology, India"},{"author_name":"Eshan Samanta","author_inst":"Global Institute of Science and Technology, India"},{"author_name":"Mary E. Sehl","author_inst":"University of California, Los Angeles"},{"author_name":"Janet S. Sinsheimer","author_inst":"University of California, Los Angeles"},{"author_name":"Debora B Perucello","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Warrison A Andrade","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Ricardo Castro","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Flavio P Veras","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Juliana E Toller-Kawahisa","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Daniele C Nascimento","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Mikhael HF de Lima","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Camila MS Silva","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Diego B Caetite","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Ronaldo B Martins","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Italo A Castro","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Marjorie C Pontelli","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabio C de Barros","author_inst":"Departamento de Ecologia e Biologia Evolutiva, Instituto de Ciencias Ambientais, Quimicas e Farmaceuticas, Universidade Federal de Sao Paulo"},{"author_name":"Natalia B do Amaral","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Marcela C Giannini","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Leticia P Bonjorno","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Isabel F Lopes","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maira N Benatti","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Rodrigo C Santana","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fernando C Vilar","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Auxiliadora-Martins","author_inst":"Divisao de Medicina Intensiva, Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rodrigo Luppino-Assad","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sergio CL de Almeida","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fabiola R de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sabrina S Batah","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Li Siyuan","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Maira N Benatti","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Thiago M Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Jose C Alves-Filho","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fernando Q Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Larissa D Cunha","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabiani G Frantz","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Tiana Kohlsdorf","author_inst":"Departamento de Biologia, Faculdade de Filosofia Ciencias e Letras de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Alexandre T Fabro","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Eurico Arruda","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rene DR de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Paulo Louzada-Junior","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Dario S Zamboni","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"public and global health"},{"rel_doi":"10.1101\/2020.08.05.20167411","rel_title":"Impact of COVID-19 on the Psychological Well-Being and Turnover Intentions of Frontline Nurses in the Community: A Cross-Sectional Study in the Philippines","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.05.20167411","rel_abs":"Purpose: This study aimed to assess fear of COVID-19 among nurses in a community setting. Methods: This study employed a cross-sectional design using self-report questionnaires. Findings: Results revealed that nurses display moderate to high fear of COVID-19 and that the female gender is correlated to fear of the virus. Moreover, the nurses fear influences their psychological distress and organizational and professional turnover intentions. Conclusion: Fear of COVID-19 is universal among nurses. There is a need to assess the factors associated with the fear to better address the nurses psychological well-being and to avoid turnover intentions.","rel_num_authors":2,"rel_authors":[{"author_name":"Janet Alexis A. De los Santos","author_inst":"Visayas State University, Philippines"},{"author_name":"Leodoro J. Labrague","author_inst":"Sultan Qaboos University, Oman"},{"author_name":"Samarjit Kar","author_inst":"NIT Durgapur, India"},{"author_name":"Anupam De","author_inst":"Haldia Institute of Technology, India"},{"author_name":"Eshan Samanta","author_inst":"Global Institute of Science and Technology, India"},{"author_name":"Mary E. Sehl","author_inst":"University of California, Los Angeles"},{"author_name":"Janet S. Sinsheimer","author_inst":"University of California, Los Angeles"},{"author_name":"Debora B Perucello","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Warrison A Andrade","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Ricardo Castro","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Flavio P Veras","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Juliana E Toller-Kawahisa","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Daniele C Nascimento","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Mikhael HF de Lima","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Camila MS Silva","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Diego B Caetite","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Ronaldo B Martins","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Italo A Castro","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Marjorie C Pontelli","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabio C de Barros","author_inst":"Departamento de Ecologia e Biologia Evolutiva, Instituto de Ciencias Ambientais, Quimicas e Farmaceuticas, Universidade Federal de Sao Paulo"},{"author_name":"Natalia B do Amaral","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Marcela C Giannini","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Leticia P Bonjorno","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Isabel F Lopes","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maira N Benatti","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Rodrigo C Santana","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fernando C Vilar","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Auxiliadora-Martins","author_inst":"Divisao de Medicina Intensiva, Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rodrigo Luppino-Assad","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sergio CL de Almeida","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fabiola R de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sabrina S Batah","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Li Siyuan","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Maira N Benatti","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Thiago M Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Jose C Alves-Filho","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fernando Q Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Larissa D Cunha","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabiani G Frantz","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Tiana Kohlsdorf","author_inst":"Departamento de Biologia, Faculdade de Filosofia Ciencias e Letras de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Alexandre T Fabro","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Eurico Arruda","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rene DR de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Paulo Louzada-Junior","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Dario S Zamboni","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"public and global health"},{"rel_doi":"10.1101\/2020.08.05.238998","rel_title":"Persistent bacterial coinfection of a COVID-19 patient caused by a genetically adapted Pseudomonas aeruginosa chronic colonizer","rel_date":"2020-08-06","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.08.05.238998","rel_abs":"This study characterized a genetically adapted Pseudomonas aeruginosa small colony variant isolated from a COVID-19 patient who suffered persistent bacterial coinfection and eventually recovered from critical illness. Specification and modification of the isolates discovered at genomic and transcriptomic levels with aligned phenotypic observations indicated that these isolates formed excessive biofilm with elevated quorum sensing systems.","rel_num_authors":9,"rel_authors":[{"author_name":"Zhao Cai","author_inst":"School  of Medicine, Southern University of Science and Technology"},{"author_name":"Yumei Liu","author_inst":"School of Medicine, Southern University of Science and Technology"},{"author_name":"XiangKe Duan","author_inst":"School of Medicine, Southern University of Science and Technology"},{"author_name":"Shuhong Han","author_inst":"School of Medicine, Southern University of Science and Technology"},{"author_name":"Yuao Zhu","author_inst":"School of Medicine, Southern University of Science and Technology"},{"author_name":"Yingdan Zhang","author_inst":"School of Medicine, Southern University of Science and Technology"},{"author_name":"Chao Zhuo","author_inst":"The state key laboratory of respiratory diseases, the first affiliated hospital of Guangzhou Medical University"},{"author_name":"Yang Liu","author_inst":"Medical Research Center, Southern University of Science and Technology Hospital, 518055, Shenzhen, China"},{"author_name":"Liang Yang","author_inst":"School of Medicine, Southern University of Science and Technology"},{"author_name":"Ricardo Castro","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Flavio P Veras","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Juliana E Toller-Kawahisa","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Daniele C Nascimento","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Mikhael HF de Lima","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Camila MS Silva","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Diego B Caetite","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Ronaldo B Martins","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Italo A Castro","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Marjorie C Pontelli","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabio C de Barros","author_inst":"Departamento de Ecologia e Biologia Evolutiva, Instituto de Ciencias Ambientais, Quimicas e Farmaceuticas, Universidade Federal de Sao Paulo"},{"author_name":"Natalia B do Amaral","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Marcela C Giannini","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Leticia P Bonjorno","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Isabel F Lopes","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maira N Benatti","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Rodrigo C Santana","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fernando C Vilar","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Auxiliadora-Martins","author_inst":"Divisao de Medicina Intensiva, Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rodrigo Luppino-Assad","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sergio CL de Almeida","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fabiola R de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sabrina S Batah","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Li Siyuan","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Maira N Benatti","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Thiago M Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Jose C Alves-Filho","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fernando Q Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Larissa D Cunha","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabiani G Frantz","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Tiana Kohlsdorf","author_inst":"Departamento de Biologia, Faculdade de Filosofia Ciencias e Letras de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Alexandre T Fabro","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Eurico Arruda","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rene DR de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Paulo Louzada-Junior","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Dario S Zamboni","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."}],"version":"1","license":"cc_by_nc","type":"new results","category":"microbiology"},{"rel_doi":"10.1101\/2020.08.06.239798","rel_title":"IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection","rel_date":"2020-08-06","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.08.06.239798","rel_abs":"The novel virus SARS-CoV-2 has infected more than 14 million people worldwide resulting in the Coronavirus disease 2019 (COVID-19). Limited information on the underlying immune mechanisms that drive disease or protection during COVID-19 severely hamper development of therapeutics and vaccines. Thus, the establishment of relevant animal models that mimic the pathobiology of the disease is urgent. Rhesus macaques infected with SARS-CoV-2 exhibit disease pathobiology similar to human COVID-19, thus serving as a relevant animal model. In the current study, we have characterized the transcriptional signatures induced in the lungs of juvenile and old rhesus macaques following SARS-CoV-2 infection. We show that genes associated with Interferon (IFN) signaling, neutrophil degranulation and innate immune pathways are significantly induced in macaque infected lungs, while pathways associated with collagen formation are downregulated. In COVID-19, increasing age is a significant risk factor for poor prognosis and increased mortality. We demonstrate that Type I IFN and Notch signaling pathways are significantly upregulated in lungs of juvenile infected macaques when compared with old infected macaques. These results are corroborated with increased peripheral neutrophil counts and neutrophil lymphocyte ratio in older individuals with COVID-19 disease. In contrast, pathways involving VEGF are downregulated in lungs of old infected macaques. Using samples from humans with SARS-CoV-2 infection and COVID-19, we validate a subset of our findings. Finally, neutrophil degranulation, innate immune system and IFN gamma signaling pathways are upregulated in both tuberculosis and COVID-19, two pulmonary diseases where neutrophils are associated with increased severity. Together, our transcriptomic studies have delineated disease pathways to improve our understanding of the immunopathogenesis of COVID-19 to facilitate the design of new therapeutics for COVID-19.","rel_num_authors":16,"rel_authors":[{"author_name":"Bruce A. Rosa","author_inst":"Washington University in Saint Louis School of Medicine"},{"author_name":"Mushtaq Ahmed","author_inst":"Washington University in St Louis"},{"author_name":"Dhiraj K. Singh","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Jose Alberto Choreno-Parra","author_inst":"Laboratory of Immunobiology and Genetics, Instituto Nacional de Enfermedades Respiratorias"},{"author_name":"Journey Cole","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Luis Armando Jimenez-Alvarez","author_inst":"Laboratory of Immunobiology and Genetics, Instituto Nacional de Enfermedades Respiratorias"},{"author_name":"Tatiana Sofia Rodriguez-Reyna","author_inst":"Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion"},{"author_name":"Bindu Singh","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Olga Golzalez","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ricardo Carrion","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Larry S. Schlesinger","author_inst":"Texas Biomedical Research Institute"},{"author_name":"John Martin","author_inst":"Washington University School of Medicine"},{"author_name":"Joaquin Zuniga","author_inst":"Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional"},{"author_name":"Makedonka Mitreva","author_inst":"Washington University School of Medicine"},{"author_name":"Shabaana A Khader","author_inst":"Washington University School of Medicine"},{"author_name":"Deepak Kaushal","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ronaldo B Martins","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Italo A Castro","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Marjorie C Pontelli","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabio C de Barros","author_inst":"Departamento de Ecologia e Biologia Evolutiva, Instituto de Ciencias Ambientais, Quimicas e Farmaceuticas, Universidade Federal de Sao Paulo"},{"author_name":"Natalia B do Amaral","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Marcela C Giannini","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Leticia P Bonjorno","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Isabel F Lopes","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maira N Benatti","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Rodrigo C Santana","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fernando C Vilar","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Auxiliadora-Martins","author_inst":"Divisao de Medicina Intensiva, Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rodrigo Luppino-Assad","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sergio CL de Almeida","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fabiola R de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sabrina S Batah","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Li Siyuan","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Maira N Benatti","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Thiago M Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Jose C Alves-Filho","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fernando Q Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Larissa D Cunha","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabiani G Frantz","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Tiana Kohlsdorf","author_inst":"Departamento de Biologia, Faculdade de Filosofia Ciencias e Letras de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Alexandre T Fabro","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Eurico Arruda","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rene DR de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Paulo Louzada-Junior","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Dario S Zamboni","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."}],"version":"1","license":"cc_by_nc_nd","type":"new results","category":"immunology"},{"rel_doi":"10.1101\/2020.08.06.240333","rel_title":"Computational Hot-Spot Analysis of the SARS-CoV-2 Receptor Binding Domain \/ ACE2 Complex","rel_date":"2020-08-06","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.08.06.240333","rel_abs":"Infection and replication of SARS CoV-2 (the virus that causes COVID-19) requires entry to the interior of host cells. In humans, a Protein-Protein Interaction (PPI) between the SARS CoV-2 Receptor-Binding Domain (RBD) and the extracellular peptidase domain of ACE2, on the surface of cells in the lower respiratory tract, is an initial step in the entry pathway. Inhibition of the SARS CoV-2 RBD \/ ACE2 PPI is currently being evaluated as a target for therapeutic and\/or prophylactic intervention. However, relatively little is known about the molecular underpinnings of this complex. Employing multiple computational platforms, we predicted  hot-spot residues in a positive control PPI (PMI \/ MDM2) and the CoV-2 RBD\/ACE2 complex. Computational alanine scanning mutagenesis was performed to predict changes in Gibbs free energy that are associated with mutating residues at the positive control (PMI\/MDM2) or SARS RBD\/ACE2 binding interface to alanine. Additionally, we used the Adaptive Poisson-Boltzmann Solver to calculate macromolecular electrostatic surfaces at the interface of the positive control PPI and SARS CoV-2 \/ ACE2 PPI. Collectively, this study illuminates predicted hot-spot residues, and clusters, at the SARS CoV-2 RBD \/ ACE2 binding interface, potentially guiding the development of reagents capable of disrupting this complex and halting COVID-19.","rel_num_authors":2,"rel_authors":[{"author_name":"Pedro A. Rosario","author_inst":"Delaware State University"},{"author_name":"Brian R McNaughton","author_inst":"Delaware State University"},{"author_name":"Dhiraj K. Singh","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Jose Alberto Choreno-Parra","author_inst":"Laboratory of Immunobiology and Genetics, Instituto Nacional de Enfermedades Respiratorias"},{"author_name":"Journey Cole","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Luis Armando Jimenez-Alvarez","author_inst":"Laboratory of Immunobiology and Genetics, Instituto Nacional de Enfermedades Respiratorias"},{"author_name":"Tatiana Sofia Rodriguez-Reyna","author_inst":"Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion"},{"author_name":"Bindu Singh","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Olga Golzalez","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ricardo Carrion","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Larry S. Schlesinger","author_inst":"Texas Biomedical Research Institute"},{"author_name":"John Martin","author_inst":"Washington University School of Medicine"},{"author_name":"Joaquin Zuniga","author_inst":"Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional"},{"author_name":"Makedonka Mitreva","author_inst":"Washington University School of Medicine"},{"author_name":"Shabaana A Khader","author_inst":"Washington University School of Medicine"},{"author_name":"Deepak Kaushal","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ronaldo B Martins","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Italo A Castro","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Marjorie C Pontelli","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabio C de Barros","author_inst":"Departamento de Ecologia e Biologia Evolutiva, Instituto de Ciencias Ambientais, Quimicas e Farmaceuticas, Universidade Federal de Sao Paulo"},{"author_name":"Natalia B do Amaral","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Marcela C Giannini","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Leticia P Bonjorno","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Isabel F Lopes","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maira N Benatti","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Rodrigo C Santana","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fernando C Vilar","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Auxiliadora-Martins","author_inst":"Divisao de Medicina Intensiva, Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rodrigo Luppino-Assad","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sergio CL de Almeida","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fabiola R de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sabrina S Batah","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Li Siyuan","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Maira N Benatti","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Thiago M Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Jose C Alves-Filho","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fernando Q Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Larissa D Cunha","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabiani G Frantz","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Tiana Kohlsdorf","author_inst":"Departamento de Biologia, Faculdade de Filosofia Ciencias e Letras de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Alexandre T Fabro","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Eurico Arruda","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rene DR de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Paulo Louzada-Junior","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Dario S Zamboni","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."}],"version":"1","license":"cc_by_nd","type":"new results","category":"biophysics"},{"rel_doi":"10.1101\/2020.08.06.238915","rel_title":"Peptide Antidotes to SARS-CoV-2 (COVID-19)","rel_date":"2020-08-06","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.08.06.238915","rel_abs":"The design of an immunogenic scaffold that serves a role in treating a pathogen, and can be rapidly and predictively modeled, has remained an elusive feat. Here, we demonstrate that SARS-BLOCK synthetic peptide scaffolds act as antidotes to SARS-CoV-2 spike protein-mediated infection of human ACE2-expressing cells. Critically, SARS-BLOCK peptides are able to potently and competitively inhibit SARS-CoV-2 S1 spike protein receptor binding domain (RBD) binding to ACE2, the main cellular entry pathway for SARS-CoV-2, while also binding to neutralizing antibodies against SARS-CoV-2. In order to create this potential therapeutic antidote-vaccine, we designed, simulated, synthesized, modeled epitopes, predicted peptide folding, and characterized behavior of a novel set of synthetic peptides. The biomimetic technology is modeled off the receptor binding motif of the SARS-CoV-2 coronavirus, and modified to provide enhanced stability and folding versus the truncated wildtype sequence. These novel peptides attain single-micromolar binding affinities for ACE2 and a neutralizing antibody against the SARS-CoV-2 receptor binding domain (RBD), and demonstrate significant reduction of infection in nanomolar doses. We also demonstrate that soluble ACE2 abrogates binding of RBD to neutralizing antibodies, which we posit is an essential immune-evasive mechanism of the virus. SARS-BLOCK is designed to \"uncloak\" the viral ACE2 coating mechanism, while also binding to neutralizing antibodies with the intention of stimulating a specific neutralizing antibody response. Our peptide scaffolds demonstrate promise for future studies evaluating specificity and sensitivity of immune responses to our antidote-vaccine. In summary, SARS-BLOCK peptides are a promising COVID-19 antidote designed to combine the benefits of a therapeutic and vaccine, effectively creating a new generation of prophylactic and reactive antiviral therapeutics whereby immune responses can be enhanced rather than blunted.","rel_num_authors":5,"rel_authors":[{"author_name":"Andre Watson","author_inst":"Ligandal Inc."},{"author_name":"Leonardo M.R. Ferreira","author_inst":"UCSF"},{"author_name":"Peter Hwang","author_inst":"UCSF"},{"author_name":"Jinbo Xu","author_inst":"Toyota Technological Institute at Chicago"},{"author_name":"Robert Stroud","author_inst":"UCSF"},{"author_name":"Luis Armando Jimenez-Alvarez","author_inst":"Laboratory of Immunobiology and Genetics, Instituto Nacional de Enfermedades Respiratorias"},{"author_name":"Tatiana Sofia Rodriguez-Reyna","author_inst":"Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion"},{"author_name":"Bindu Singh","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Olga Golzalez","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ricardo Carrion","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Larry S. Schlesinger","author_inst":"Texas Biomedical Research Institute"},{"author_name":"John Martin","author_inst":"Washington University School of Medicine"},{"author_name":"Joaquin Zuniga","author_inst":"Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional"},{"author_name":"Makedonka Mitreva","author_inst":"Washington University School of Medicine"},{"author_name":"Shabaana A Khader","author_inst":"Washington University School of Medicine"},{"author_name":"Deepak Kaushal","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ronaldo B Martins","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Italo A Castro","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Marjorie C Pontelli","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabio C de Barros","author_inst":"Departamento de Ecologia e Biologia Evolutiva, Instituto de Ciencias Ambientais, Quimicas e Farmaceuticas, Universidade Federal de Sao Paulo"},{"author_name":"Natalia B do Amaral","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Marcela C Giannini","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Leticia P Bonjorno","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Isabel F Lopes","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maira N Benatti","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Rodrigo C Santana","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fernando C Vilar","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Auxiliadora-Martins","author_inst":"Divisao de Medicina Intensiva, Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rodrigo Luppino-Assad","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sergio CL de Almeida","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fabiola R de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sabrina S Batah","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Li Siyuan","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Maira N Benatti","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Thiago M Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Jose C Alves-Filho","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fernando Q Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Larissa D Cunha","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabiani G Frantz","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Tiana Kohlsdorf","author_inst":"Departamento de Biologia, Faculdade de Filosofia Ciencias e Letras de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Alexandre T Fabro","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Eurico Arruda","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rene DR de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Paulo Louzada-Junior","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Dario S Zamboni","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."}],"version":"1","license":"cc_by_nc_nd","type":"new results","category":"bioengineering"},{"rel_doi":"10.1101\/2020.08.06.240192","rel_title":"Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors","rel_date":"2020-08-06","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.08.06.240192","rel_abs":"The number of new cases world-wide for the COVID-19 disease is increasing dramatically, while efforts to contain Severe Acute Respiratory Syndrome Coronavirus 2 is producing varied results in different countries. There are three key SARS-CoV-2 enzymes potentially targetable with antivirals: papain-like protease (PLpro), main protease (Mpro), and RNA-dependent RNA polymerase. Of these, PLpro is an especially attractive target because it plays an essential role in several viral replication processes, including cleavage and maturation of viral polyproteins, assembly of the replicase-transcriptase complex (RTC), and disruption of host viral response machinery to facilitate viral proliferation and replication. Moreover, this enzyme is conserved across different coronaviruses and promising inhibitors have already been discovered for its SARS-CoV variant. Here we report a substantive body of structural, biochemical, and virus replication studies that identify several inhibitors of the enzyme from SARS-CoV-2 in both wild-type and mutant forms. These efforts include the first structures of wild-type PLpro, the active site C111S mutant, and their complexes with inhibitors, determined at 1.60-2.70 Angstroms. This collection of structures provides fundamental molecular and mechanistic insight to PLpro, and critically, illustrates details for inhibitors recognition and interactions. All presented compounds inhibit the peptidase activity of PLpro in vitro, and some molecules block SARS-CoV-2 replication in cell culture assays. These collated findings will accelerate further structure-based drug design efforts targeting PLpro, with the ultimate goal of identifying high-affinity inhibitors of clinical value for SARS-CoV-2.","rel_num_authors":21,"rel_authors":[{"author_name":"Jerzy Osipiuk","author_inst":"UChicago\/ANL"},{"author_name":"Saara-Anne Azizi","author_inst":"UChicago"},{"author_name":"Steve Dvorkin","author_inst":"UChicago"},{"author_name":"Michael Endres","author_inst":"UChicago\/ANL"},{"author_name":"Robert Jedrzejczak","author_inst":"UChicago\/ANL"},{"author_name":"Krysten A. Jones","author_inst":"UChicago"},{"author_name":"Soowon Kang","author_inst":"UChicago"},{"author_name":"Rahul S. Kathayat","author_inst":"UChicago"},{"author_name":"Youngchang Kim","author_inst":"UChicago\/ANL"},{"author_name":"Vladislav G. Lisnyak","author_inst":"UChicago"},{"author_name":"Samantha L. Maki","author_inst":"UChicago"},{"author_name":"Vlad Nicolaescu","author_inst":"UChicago"},{"author_name":"Cooper A. Taylor","author_inst":"UChicago"},{"author_name":"Christine Tesar","author_inst":"UChicago\/ANL"},{"author_name":"Yu-An Zhang","author_inst":"UChicago"},{"author_name":"Zhiyao Zhou","author_inst":"UChicago"},{"author_name":"Glenn Randall","author_inst":"UChicago"},{"author_name":"Karolina Michalska","author_inst":"UChicago\/ANL"},{"author_name":"Scott A. Snyder","author_inst":"UChicago"},{"author_name":"Bryan C. Dickinson","author_inst":"UChicago"},{"author_name":"Andrzej Joachimiak","author_inst":"UChicago\/ANL"},{"author_name":"Marcela C Giannini","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Leticia P Bonjorno","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Isabel F Lopes","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maira N Benatti","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Rodrigo C Santana","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fernando C Vilar","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Auxiliadora-Martins","author_inst":"Divisao de Medicina Intensiva, Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rodrigo Luppino-Assad","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sergio CL de Almeida","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fabiola R de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sabrina S Batah","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Li Siyuan","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Maira N Benatti","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Thiago M Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Jose C Alves-Filho","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fernando Q Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Larissa D Cunha","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabiani G Frantz","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Tiana Kohlsdorf","author_inst":"Departamento de Biologia, Faculdade de Filosofia Ciencias e Letras de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Alexandre T Fabro","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Eurico Arruda","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rene DR de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Paulo Louzada-Junior","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Dario S Zamboni","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."}],"version":"1","license":"cc_by_nc_nd","type":"new results","category":"molecular biology"},{"rel_doi":"10.1101\/2020.08.06.234674","rel_title":"Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate","rel_date":"2020-08-06","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.08.06.234674","rel_abs":"Vaccine efforts against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the current COVID-19 pandemic are focused on SARS-CoV-2 spike glycoprotein, the primary target for neutralizing antibodies. Here, we performed cryo-EM and site-specific glycan analysis of one of the leading subunit vaccine candidates from Novavax based on a full-length spike protein formulated in polysorbate 80 (PS 80) detergent. Our studies reveal a stable prefusion conformation of the spike immunogen with slight differences in the S1 subunit compared to published spike ectodomain structures. Interestingly, we also observed novel interactions between the spike trimers allowing formation of higher order spike complexes. This study confirms the structural integrity of the full-length spike protein immunogen and provides a basis for interpreting immune responses to this multivalent nanoparticle immunogen.","rel_num_authors":18,"rel_authors":[{"author_name":"Sandhya Bangaru","author_inst":"Scripps Research"},{"author_name":"Gabriel Ozorowski","author_inst":"Scripps Research Institute"},{"author_name":"Hannah L Turner","author_inst":"The Scripps Research Institute"},{"author_name":"Aleksandar Antanasijevic","author_inst":"Scripps Research"},{"author_name":"Deli Huang","author_inst":"The Scripps Research Institute"},{"author_name":"Xiaoning Wang","author_inst":"Scripps Research"},{"author_name":"Jonathan L Torres","author_inst":"Scripps Research"},{"author_name":"Jolene K Diedrich","author_inst":"The Scripps Research Institute and The Salk Institute for Biological Studies"},{"author_name":"Jing-Hui Tian","author_inst":"Novavax, Inc."},{"author_name":"Alyse D. Portnoff","author_inst":"Novavax, Inc."},{"author_name":"Nita Patel","author_inst":"Novavax, Inc."},{"author_name":"Michael J. Massare","author_inst":"Novavax, Inc."},{"author_name":"John Robert Yates III","author_inst":"The Scripps Research Institute"},{"author_name":"David Nemazee","author_inst":"The Scripps Research Institute"},{"author_name":"James C. Paulson","author_inst":"The Scripps Research Institute"},{"author_name":"Greg Glenn","author_inst":"Novavax, Inc."},{"author_name":"Gale Smith","author_inst":"Novavax, Inc."},{"author_name":"Andrew B. Ward","author_inst":"The Scripps Research Institute"},{"author_name":"Scott A. Snyder","author_inst":"UChicago"},{"author_name":"Bryan C. Dickinson","author_inst":"UChicago"},{"author_name":"Andrzej Joachimiak","author_inst":"UChicago\/ANL"},{"author_name":"Marcela C Giannini","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Leticia P Bonjorno","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Isabel F Lopes","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maira N Benatti","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Rodrigo C Santana","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fernando C Vilar","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Auxiliadora-Martins","author_inst":"Divisao de Medicina Intensiva, Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rodrigo Luppino-Assad","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sergio CL de Almeida","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fabiola R de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sabrina S Batah","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Li Siyuan","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Maira N Benatti","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Thiago M Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Jose C Alves-Filho","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fernando Q Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Larissa D Cunha","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabiani G Frantz","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Tiana Kohlsdorf","author_inst":"Departamento de Biologia, Faculdade de Filosofia Ciencias e Letras de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Alexandre T Fabro","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Eurico Arruda","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rene DR de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Paulo Louzada-Junior","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Dario S Zamboni","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."}],"version":"1","license":"cc_by","type":"new results","category":"immunology"},{"rel_doi":"10.1101\/2020.07.30.20164939","rel_title":"Evaluating the impact of non-pharmaceutical interventions for SARS-CoV-2 on a global scale","rel_date":"2020-08-05","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.07.30.20164939","rel_abs":"In the absence of a viable pharmaceutical intervention for SARS-CoV-2, governments have implemented a range of non-pharmaceutical interventions (NPIs) to curb the spread of infection of the virus and the disease caused by the virus, now known as COVID-19. Given the associated social and economic costs, it is critical to enumerate the individual impacts of NPIs to aid in decision-making moving forward. We used globally reported SARS-CoV-2 cases to fit a Bayesian model framework to estimate transmission associated with NPIs in 26 countries and 34 US states. Using a mixed effects model with country level random effects, we compared the relative impact of other NPIs to national-level household confinement measures and evaluated the impact of NPIs on the global trajectory of the COVID-19 pandemic over time. We observed heterogeneous impacts of the easing of restrictions and estimated an overall reduction in infection of 23% (95% CI: 18-27%) associated with household confinement, 10% (95% CI: 1-18%) with limits on gatherings, 12% (95% CI: 5-19%) with school closures and 17% (95% CI: 6-28%) with mask policies. We estimated a 12% (95% CI: 9-15%) reduction in transmission associated with NPIs overall. The implementation of NPIs have substantially reduced acceleration of COVID-19. At this early time point, we cannot determine the impact of the easing of restrictions and there is a need for continual assessment of context specific effectiveness of NPIs as more data become available.","rel_num_authors":9,"rel_authors":[{"author_name":"Rachel T Esra","author_inst":"University of Geneva"},{"author_name":"Lise Jamesion","author_inst":"Health Economics and Epidemiology Research Office"},{"author_name":"Matthew P Fox","author_inst":"Department of Global Health, Boston University School of Public Health"},{"author_name":"Daniel Letswalo","author_inst":"Health Economics and Epidemiology Research Office"},{"author_name":"Nkosinathi Ngcobo","author_inst":"Health Economics and Epidemiology Research Office"},{"author_name":"Sithabile Mngadi","author_inst":"Health Economics and Epidemiology Research Office"},{"author_name":"Janne Global Estill","author_inst":"University of Geneva"},{"author_name":"Gesine Meyer-Rath","author_inst":"Health Economics and Epidemiology Research Office"},{"author_name":"Olivia Keiser","author_inst":"University of Geneva"},{"author_name":"Alyse D. Portnoff","author_inst":"Novavax, Inc."},{"author_name":"Nita Patel","author_inst":"Novavax, Inc."},{"author_name":"Michael J. Massare","author_inst":"Novavax, Inc."},{"author_name":"John Robert Yates III","author_inst":"The Scripps Research Institute"},{"author_name":"David Nemazee","author_inst":"The Scripps Research Institute"},{"author_name":"James C. Paulson","author_inst":"The Scripps Research Institute"},{"author_name":"Greg Glenn","author_inst":"Novavax, Inc."},{"author_name":"Gale Smith","author_inst":"Novavax, Inc."},{"author_name":"Andrew B. Ward","author_inst":"The Scripps Research Institute"},{"author_name":"Scott A. Snyder","author_inst":"UChicago"},{"author_name":"Bryan C. Dickinson","author_inst":"UChicago"},{"author_name":"Andrzej Joachimiak","author_inst":"UChicago\/ANL"},{"author_name":"Marcela C Giannini","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Leticia P Bonjorno","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Isabel F Lopes","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maira N Benatti","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Rodrigo C Santana","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fernando C Vilar","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Auxiliadora-Martins","author_inst":"Divisao de Medicina Intensiva, Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rodrigo Luppino-Assad","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sergio CL de Almeida","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fabiola R de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sabrina S Batah","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Li Siyuan","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Maira N Benatti","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Thiago M Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Jose C Alves-Filho","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fernando Q Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Larissa D Cunha","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabiani G Frantz","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Tiana Kohlsdorf","author_inst":"Departamento de Biologia, Faculdade de Filosofia Ciencias e Letras de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Alexandre T Fabro","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Eurico Arruda","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rene DR de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Paulo Louzada-Junior","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Dario S Zamboni","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.02.232645","rel_title":"Host metabolic reprogramming in response to SARS-Cov-2 infection","rel_date":"2020-08-05","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.08.02.232645","rel_abs":"Understanding the pathogenesis of SARS-CoV-2 is important for developing effective treatment strategies. Viruses hijack the host metabolism to redirect the resources for their replication and survival. How SARS-CoV-2 influences the host metabolism is still unclear. In this study, we analyzed transcriptomic data obtained from different human respiratory cell lines and patient samples (Swab, PBMC, lung biopsy, BALF) to understand the metabolic alterations in response to SARS-CoV-2 infection. For this purpose, the expression pattern of metabolic genes in the human genome-scale metabolic network model Recon3D was explored. We identified metabolic genes and pathways and reporter metabolites under each SARS-CoV-2-infected condition and compared them to identify common and unique changes in the metabolism. Our analysis revealed host-dependent dysregulation of glycolysis, mitochondrial metabolism, amino acid metabolism, glutathione metabolism, polyamine synthesis, and lipid metabolism. We observed different metabolic changes that are pro- and antiviral in nature. We generated hypotheses on how antiviral metabolism can be targeted\/enhanced for reducing viral titers. These warrant further exploration with more samples and in vitro studies to test predictions.","rel_num_authors":4,"rel_authors":[{"author_name":"S T R Moolamalla","author_inst":"Centre for Computational Natural Sciences and Bioinformatics, International Institute of Information Technology, Hyderabad-500032, India"},{"author_name":"Ruchi Chauhan","author_inst":"Centre for Computational Natural Sciences and Bioinformatics, International Institute of Information Technology, Hyderabad-500032, India"},{"author_name":"U Deva Priyakumar","author_inst":"Centre for Computational Natural Sciences and Bioinformatics, International Institute of Information Technology, Hyderabad-500032, India"},{"author_name":"P K Vinod","author_inst":"Centre for Computational Natural Sciences and Bioinformatics, International Institute of Information Technology, Hyderabad-500032, India"},{"author_name":"Nkosinathi Ngcobo","author_inst":"Health Economics and Epidemiology Research Office"},{"author_name":"Sithabile Mngadi","author_inst":"Health Economics and Epidemiology Research Office"},{"author_name":"Janne Global Estill","author_inst":"University of Geneva"},{"author_name":"Gesine Meyer-Rath","author_inst":"Health Economics and Epidemiology Research Office"},{"author_name":"Olivia Keiser","author_inst":"University of Geneva"},{"author_name":"Alyse D. Portnoff","author_inst":"Novavax, Inc."},{"author_name":"Nita Patel","author_inst":"Novavax, Inc."},{"author_name":"Michael J. Massare","author_inst":"Novavax, Inc."},{"author_name":"John Robert Yates III","author_inst":"The Scripps Research Institute"},{"author_name":"David Nemazee","author_inst":"The Scripps Research Institute"},{"author_name":"James C. Paulson","author_inst":"The Scripps Research Institute"},{"author_name":"Greg Glenn","author_inst":"Novavax, Inc."},{"author_name":"Gale Smith","author_inst":"Novavax, Inc."},{"author_name":"Andrew B. Ward","author_inst":"The Scripps Research Institute"},{"author_name":"Scott A. Snyder","author_inst":"UChicago"},{"author_name":"Bryan C. Dickinson","author_inst":"UChicago"},{"author_name":"Andrzej Joachimiak","author_inst":"UChicago\/ANL"},{"author_name":"Marcela C Giannini","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Leticia P Bonjorno","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Isabel F Lopes","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maira N Benatti","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Rodrigo C Santana","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fernando C Vilar","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Auxiliadora-Martins","author_inst":"Divisao de Medicina Intensiva, Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rodrigo Luppino-Assad","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sergio CL de Almeida","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fabiola R de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sabrina S Batah","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Li Siyuan","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Maira N Benatti","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Thiago M Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Jose C Alves-Filho","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fernando Q Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Larissa D Cunha","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabiani G Frantz","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Tiana Kohlsdorf","author_inst":"Departamento de Biologia, Faculdade de Filosofia Ciencias e Letras de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Alexandre T Fabro","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Eurico Arruda","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rene DR de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Paulo Louzada-Junior","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Dario S Zamboni","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."}],"version":"1","license":"cc_no","type":"new results","category":"bioinformatics"},{"rel_doi":"10.1101\/2020.08.05.237651","rel_title":"Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity","rel_date":"2020-08-05","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.08.05.237651","rel_abs":"Antiviral therapy is urgently needed to combat the coronavirus disease 2019 (COVID-19) pandemic, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The protease inhibitor camostat mesylate inhibits SARS-CoV-2 infection of lung cells by blocking the virus-activating host cell protease TMPRSS2. Camostat mesylate has been approved for treatment of pancreatitis in Japan and is currently being repurposed for COVID-19 treatment. However, potential mechanisms of viral resistance as well as camostat mesylate metabolization and antiviral activity of metabolites are unclear. Here, we show that SARS-CoV-2 can employ TMPRSS2-related host cell proteases for activation and that several of them are expressed in viral target cells. However, entry mediated by these proteases was blocked by camostat mesylate. The camostat metabolite GBPA inhibited the activity of recombinant TMPRSS2 with reduced efficiency as compared to camostat mesylate and was rapidly generated in the presence of serum. Importantly, the infection experiments in which camostat mesylate was identified as a SARS-CoV-2 inhibitor involved preincubation of target cells with camostat mesylate in the presence of serum for 2 h and thus allowed conversion of camostat mesylate into GBPA. Indeed, when the antiviral activities of GBPA and camostat mesylate were compared in this setting, no major differences were identified. Our results indicate that use of TMPRSS2-related proteases for entry into target cells will not render SARS-CoV-2 camostat mesylate resistant. Moreover, the present and previous findings suggest that the peak concentrations of GBPA established after the clinically approved camostat mesylate dose (600 mg\/day) will result in antiviral activity.","rel_num_authors":19,"rel_authors":[{"author_name":"Markus Hoffmann","author_inst":"Deutsches Primatenzentrum GmbH - Leibniz-Institut fur Primatenforschung; Faculty of Biology and Psychology, University Goettingen, 37073 Goettingen, Germany"},{"author_name":"Heike Hofmann-Winkler","author_inst":"Deutsches Primatenzentrum GmbH - Leibniz-Institut fur Primatenforschung"},{"author_name":"Joan C. Smith","author_inst":"Google, Inc., New York City, NY 10011, USA; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA"},{"author_name":"Nadine Krueger","author_inst":"Deutsches Primatenzentrum GmbH, Infection Biology Unit"},{"author_name":"Lambert K. Sorensen","author_inst":"Department of Forensic Medicine, Aarhus University, Denmark"},{"author_name":"Ole S. Sogaard","author_inst":"Department of Clinical Medicine, Aarhus University, 8200 Aarhus, Denmark; Department of Infectious Diseases, Aarhus University Hospital, 8200 Aarhus, Denmark"},{"author_name":"Jorgen Bo Hasselstrom","author_inst":"Department of Forensic Medicine, Aarhus University, Denmark"},{"author_name":"Michael Winkler","author_inst":"Deutsches Primatenzentrum GmbH, Infection Biology Unit"},{"author_name":"Tim Hempel","author_inst":"Freie Universitaet Berlin, Department of Mathematics and Computer Science, Berlin, Germany; Freie Universitaet Berlin, Department of Physics, Berlin, Germany"},{"author_name":"Lluis Raich","author_inst":"Freie Universitaet Berlin, Department of Mathematics and Computer Science, Berlin, Germany"},{"author_name":"Simon Olsson","author_inst":"Freie Universitaet Berlin, Department of Mathematics and Computer Science, Berlin, Germany"},{"author_name":"Takashi Yamazoe","author_inst":"Discovery Technology Research Laboratories, Ono Pharmaceutical Co., Ltd., Osaka 618-8585, Japan"},{"author_name":"Katsura Yamatsuta","author_inst":"Discovery Technology Research Laboratories, Ono Pharmaceutical Co., Ltd., Osaka 618-8585, Japan"},{"author_name":"Hirotaka Mizuno","author_inst":"Discovery Technology Research Laboratories, Ono Pharmaceutical Co., Ltd., Osaka 618-8585, Japan"},{"author_name":"Stephan Ludwig","author_inst":"Institute of Virology (IVM), Westfaelische Wilhelms-Universitaet, 48149 Muenster, Germany; Cluster of Excellence - Cells in Motion -, Westfaelische Wilhelms-Uni"},{"author_name":"Frank Noe","author_inst":"Freie Universitaet Berlin, Department of Mathematics and Computer Science, Berlin, Germany; Freie Universitaet Berlin, Department of Physics, Berlin, Germany; R"},{"author_name":"Jason M. Sheltzer","author_inst":"Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA"},{"author_name":"Mads Kjolby","author_inst":"Danish Diabetes Academy and DANDRITE, Department of Biomedicine, Aarhus University, 8000 Aarhus, Denmark; Department of Clinical Pharmacology, Aarhus University"},{"author_name":"Stefan Poehlmann","author_inst":"Deutsches Primatenzentrum GmbH - Leibniz-Institut fur Primatenforschung; Faculty of Biology and Psychology, University Goettingen, 37073 Goettingen, Germany"},{"author_name":"Bryan C. Dickinson","author_inst":"UChicago"},{"author_name":"Andrzej Joachimiak","author_inst":"UChicago\/ANL"},{"author_name":"Marcela C Giannini","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Leticia P Bonjorno","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Isabel F Lopes","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maira N Benatti","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Rodrigo C Santana","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fernando C Vilar","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Auxiliadora-Martins","author_inst":"Divisao de Medicina Intensiva, Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rodrigo Luppino-Assad","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sergio CL de Almeida","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fabiola R de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sabrina S Batah","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Li Siyuan","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Maira N Benatti","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Thiago M Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Jose C Alves-Filho","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fernando Q Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Larissa D Cunha","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabiani G Frantz","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Tiana Kohlsdorf","author_inst":"Departamento de Biologia, Faculdade de Filosofia Ciencias e Letras de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Alexandre T Fabro","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Eurico Arruda","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rene DR de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Paulo Louzada-Junior","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Dario S Zamboni","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."}],"version":"1","license":"cc_by_nc_nd","type":"new results","category":"molecular biology"},{"rel_doi":"10.1101\/2020.08.05.237867","rel_title":"Rapid GMP-compliant expansion of SARS-CoV-2-specific T cells from convalescent donors for use as an allogeneic cell therapy for COVID-19","rel_date":"2020-08-05","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.08.05.237867","rel_abs":"COVID-19 disease caused by the SARS-CoV-2 virus is characterized by dysregulation of effector T cells and accumulation of exhausted T cells. T cell responses to viruses can be corrected by adoptive cellular therapy using donor-derived virus-specific T cells. Here we show that SARS-CoV-2-exposed blood donations contain CD4 and CD8 memory T cells specific for SARS-CoV-2 spike, nucleocapsid and membrane antigens. These peptides can be used to isolate virus-specific T cells in a GMP-compliant process. These T cells can be rapidly expanded using GMP-compliant reagents for use as a therapeutic product. Memory and effector phenotypes are present in the selected virus-specific T cells, but our method rapidly expands the desirable central memory phenotype. A manufacturing yield ranging from 1010 to 1011 T cells can be obtained within 21 days culture. Thus, multiple therapeutic doses of virus-specific T cells can be rapidly generated from convalescent donors for treatment of COVID-19 patients\n\nOne Sentence SummaryCD4+ and CD8+ T cells specific for SARS-CoV-2 can be isolated from convalescent donors and rapidly expanded to therapeutic doses at GMP standard, maintaining the desired central memory phenotype required for protective immune responses against severe COVID-19 infections.","rel_num_authors":9,"rel_authors":[{"author_name":"Rachel S Cooper","author_inst":"Scottish National Blood Transfusion Service"},{"author_name":"Alasdair R Fraser","author_inst":"Scottish National Blood Transfusion Service"},{"author_name":"Linda Smith","author_inst":"Scottish National Blood Transfusion Service"},{"author_name":"Paul Burgoyne","author_inst":"Scottish National Blood Transfusion Service"},{"author_name":"Stuart N Imlach","author_inst":"Scottish National Blood Transfusion Service"},{"author_name":"Lisa M Jarvis","author_inst":"Scottish National Blood Transfusion Service"},{"author_name":"Sharon Zahara","author_inst":"Scottish National Blood Transfusion Service"},{"author_name":"Marc L Turner","author_inst":"Scottish National Blood Transfusion Service"},{"author_name":"John DM Campbell","author_inst":"Scottish National Blood Transfusion Service"},{"author_name":"Lluis Raich","author_inst":"Freie Universitaet Berlin, Department of Mathematics and Computer Science, Berlin, Germany"},{"author_name":"Simon Olsson","author_inst":"Freie Universitaet Berlin, Department of Mathematics and Computer Science, Berlin, Germany"},{"author_name":"Takashi Yamazoe","author_inst":"Discovery Technology Research Laboratories, Ono Pharmaceutical Co., Ltd., Osaka 618-8585, Japan"},{"author_name":"Katsura Yamatsuta","author_inst":"Discovery Technology Research Laboratories, Ono Pharmaceutical Co., Ltd., Osaka 618-8585, Japan"},{"author_name":"Hirotaka Mizuno","author_inst":"Discovery Technology Research Laboratories, Ono Pharmaceutical Co., Ltd., Osaka 618-8585, Japan"},{"author_name":"Stephan Ludwig","author_inst":"Institute of Virology (IVM), Westfaelische Wilhelms-Universitaet, 48149 Muenster, Germany; Cluster of Excellence - Cells in Motion -, Westfaelische Wilhelms-Uni"},{"author_name":"Frank Noe","author_inst":"Freie Universitaet Berlin, Department of Mathematics and Computer Science, Berlin, Germany; Freie Universitaet Berlin, Department of Physics, Berlin, Germany; R"},{"author_name":"Jason M. Sheltzer","author_inst":"Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA"},{"author_name":"Mads Kjolby","author_inst":"Danish Diabetes Academy and DANDRITE, Department of Biomedicine, Aarhus University, 8000 Aarhus, Denmark; Department of Clinical Pharmacology, Aarhus University"},{"author_name":"Stefan Poehlmann","author_inst":"Deutsches Primatenzentrum GmbH - Leibniz-Institut fur Primatenforschung; Faculty of Biology and Psychology, University Goettingen, 37073 Goettingen, Germany"},{"author_name":"Bryan C. Dickinson","author_inst":"UChicago"},{"author_name":"Andrzej Joachimiak","author_inst":"UChicago\/ANL"},{"author_name":"Marcela C Giannini","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Leticia P Bonjorno","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Isabel F Lopes","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maira N Benatti","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Rodrigo C Santana","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fernando C Vilar","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Auxiliadora-Martins","author_inst":"Divisao de Medicina Intensiva, Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rodrigo Luppino-Assad","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sergio CL de Almeida","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fabiola R de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sabrina S Batah","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Li Siyuan","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Maira N Benatti","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Thiago M Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Jose C Alves-Filho","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fernando Q Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Larissa D Cunha","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabiani G Frantz","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Tiana Kohlsdorf","author_inst":"Departamento de Biologia, Faculdade de Filosofia Ciencias e Letras de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Alexandre T Fabro","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Eurico Arruda","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rene DR de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Paulo Louzada-Junior","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Dario S Zamboni","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."}],"version":"1","license":"cc_by_nc_nd","type":"new results","category":"immunology"},{"rel_doi":"10.1101\/2020.08.05.237339","rel_title":"Evolutionary dynamics of SARS-CoV-2 nucleocapsid protein (N protein) and its consequences","rel_date":"2020-08-05","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.08.05.237339","rel_abs":"The emerging novel coronavirus SARS-CoV-2 has created a global confusing pandemic health crisis that warrants an accurate and detailed characterization of the rapidly evolving viral genome for understanding its epidemiology, pathogenesis and containment. We explored 61,485 sequences of the Nucleocapsid (N) protein, a potent diagnostic and prophylactic target, for identifying the mutations to review their roles in RT-PCR based diagnosis and observe consequent impacts. Compared to the Wuhan reference strain, a total of 1034 unique nucleotide mutations were identified in the mutant strains (49.15%, n=30,221) globally. Of these mutations, 367 occupy primer binding sites including 3-end mismatch to primer-pair of 11 well characterized primer sets. Noteworthy, CDC (USA) recommended N2 primer set contained lower mismatch than the other primer sets. Moreover, 684 amino acid (aa) substitutions located across 317 (75.66% of total aa) unique positions including 82, 21, and 83 of those in RNA binding N-terminal domain (NTD), SR-rich region, and C-terminal dimerization domain (CTD), respectively. Moreover, 11 in-frame deletions were revealed, mostly (n =10) within the highly flexible linker region, and the rest within the NTD region. Furthermore, we predicted the possible consequences of high-frequency mutations ([&ge;] 20) and deletions on the tertiary structure of the N protein. Remarkably, we observed that high frequency (67.94% of mutated sequences) coevolving mutations (R203K and G204R) destabilized and decreased overall structural flexibility. Despite being proposed as the alternate target to spike protein for vaccine and therapeutics, ongoing nonsynonymous evolution of the N protein may challenge the endeavors, thus need further immunoinformatics analyses. Therefore, continuous monitoring is required for tracing the ongoing evolution of the SARS-CoV-2 N protein in prophylactic and diagnostic interventions.","rel_num_authors":9,"rel_authors":[{"author_name":"M. Shaminur Rahman","author_inst":"Dhaka University"},{"author_name":"M. Rafiul Islam","author_inst":"Dhaka University"},{"author_name":"A. S. M. Rubayet Ul Alam","author_inst":"Jashore University of Science and Technology"},{"author_name":"Israt Islam","author_inst":"Dhaka University"},{"author_name":"M. Nazmul Hoque","author_inst":"Dhaka university"},{"author_name":"Salma Akter","author_inst":"Dhaka University"},{"author_name":"Md. Mizanur Rahaman","author_inst":"Dhaka University"},{"author_name":"Munawar Sultana","author_inst":"Dhaka University"},{"author_name":"M. Anwar Hossain","author_inst":"Dhaka University"},{"author_name":"Lluis Raich","author_inst":"Freie Universitaet Berlin, Department of Mathematics and Computer Science, Berlin, Germany"},{"author_name":"Simon Olsson","author_inst":"Freie Universitaet Berlin, Department of Mathematics and Computer Science, Berlin, Germany"},{"author_name":"Takashi Yamazoe","author_inst":"Discovery Technology Research Laboratories, Ono Pharmaceutical Co., Ltd., Osaka 618-8585, Japan"},{"author_name":"Katsura Yamatsuta","author_inst":"Discovery Technology Research Laboratories, Ono Pharmaceutical Co., Ltd., Osaka 618-8585, Japan"},{"author_name":"Hirotaka Mizuno","author_inst":"Discovery Technology Research Laboratories, Ono Pharmaceutical Co., Ltd., Osaka 618-8585, Japan"},{"author_name":"Stephan Ludwig","author_inst":"Institute of Virology (IVM), Westfaelische Wilhelms-Universitaet, 48149 Muenster, Germany; Cluster of Excellence - Cells in Motion -, Westfaelische Wilhelms-Uni"},{"author_name":"Frank Noe","author_inst":"Freie Universitaet Berlin, Department of Mathematics and Computer Science, Berlin, Germany; Freie Universitaet Berlin, Department of Physics, Berlin, Germany; R"},{"author_name":"Jason M. Sheltzer","author_inst":"Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA"},{"author_name":"Mads Kjolby","author_inst":"Danish Diabetes Academy and DANDRITE, Department of Biomedicine, Aarhus University, 8000 Aarhus, Denmark; Department of Clinical Pharmacology, Aarhus University"},{"author_name":"Stefan Poehlmann","author_inst":"Deutsches Primatenzentrum GmbH - Leibniz-Institut fur Primatenforschung; Faculty of Biology and Psychology, University Goettingen, 37073 Goettingen, Germany"},{"author_name":"Bryan C. Dickinson","author_inst":"UChicago"},{"author_name":"Andrzej Joachimiak","author_inst":"UChicago\/ANL"},{"author_name":"Marcela C Giannini","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Leticia P Bonjorno","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Isabel F Lopes","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maira N Benatti","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Rodrigo C Santana","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fernando C Vilar","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Auxiliadora-Martins","author_inst":"Divisao de Medicina Intensiva, Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rodrigo Luppino-Assad","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sergio CL de Almeida","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fabiola R de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sabrina S Batah","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Li Siyuan","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Maira N Benatti","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Thiago M Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Jose C Alves-Filho","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fernando Q Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Larissa D Cunha","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabiani G Frantz","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Tiana Kohlsdorf","author_inst":"Departamento de Biologia, Faculdade de Filosofia Ciencias e Letras de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Alexandre T Fabro","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Eurico Arruda","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rene DR de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Paulo Louzada-Junior","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Dario S Zamboni","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."}],"version":"1","license":"cc_by_nd","type":"new results","category":"evolutionary biology"}]}



